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 Abstract 
 
The mechanisms by which mitochondrial metabolism supports cancer anabolism are still 
unclear. Here, we unexpectedly find that genetic and pharmacological inactivation of Pyruvate 
Dehydrogenase A1 (PDHA1), a subunit of pyruvate dehydrogenase complex (PDC) inhibits 
prostate cancer development in different mouse and human xenograft tumour models by 
affecting lipid biosynthesis. Mechanistically, we show that in prostate cancer, PDC localizes in 
both mitochondria and nucleus. While nuclear PDC controls the expression of Sterol regulatory 
element-binding transcription factor (SREBF) target genes by mediating histone acetylation, 
mitochondrial PDC provides cytosolic citrate for lipid synthesis in a coordinated effort to sustain 
anabolism. In line with these evidence, we find that PDHA1 and the PDC activator, Pyruvate 
dehydrogenase phosphatase 1 (PDP1), are frequently amplified and overexpressed at both gene 
and protein level in prostate tumours. Taken together, these findings demonstrate that both 
mitochondrial and nuclear PDC sustain prostate tumourigenesis by controlling lipid biosynthesis 
thereby pointing at this complex as a novel target for cancer therapy. 
 
Résumé 
 
Les mécanismes associés à la fonction mitochondriale ont participé au métabolisme anabolique 
qui a causé le cancer sont encore peu clair. Nous avons découvert que l'inactivation de la 
pyruvate déshydrogénase A1 (PDHA1), une sous-unité du complexe pyruvate déshydrogénase 
(PDC), par des moyens génétiques et pharmacologiques, inhibe le développement du cancer de 
la prostate dans différents murins et humains de xénogreffe modèles. Cet effet est à la 
modulation de la biosynthèse des lipides. Le PDC est localisé dans la fois dans la mitochondrie 
et dans le noyau. Le PDC nucléaire contrôle l'expression de gènes cibles du facteur de 
transcription Sterol regulating element-binding (SREBF) en médiant l'acétylation des histones, 
tandis que le PDC mitochondrial fourni du citrate, un intermédiaire métabolique nécessaire à la 
biosynthèse des lipides. Ainsi, le PDC nucléaire et le PDC mitochondrial facilitent le 
métabolisme anabolique de façon coordonnée. De même, PDHA1 et activateur de PDC, pyruvate 
déshydrogénase phosphatase 1 (PDP1), sont fréquemment amplifiés et surexprimés au niveau 
génétique et protéique dans les tumeurs de la prostate. Dans l'ensemble, nos résultats démontrent 
que les complexes PDC nucléaires et mitochondriaux supportent le processus de tumorigenèse 
dans le cas du cancer de la prostate en promouvant la biosynthèse des lipides. Nos observations 
placent les complexes PDC comme une nouvelle cible thérapeutique pour le traitement du 
cancer. 
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3. Introduction 
3.1 Cancer metabolism 
Cancer metabolism is one of the oldest fields of study in cancer biology, preceding the discovery 
of oncogenes and tumor suppressors by some 50 years. The initial observations by Otto Warburg 
and his contemporaries during the early twentieth century suggested that core cellular 
metabolism was skewed during the process of malignant transformation1, however, the oncogene 
revolution since the discovery of the first oncogene, SRC (a proto-oncogene tyrosine-protein 
kinase)2 and the emerge of genetic technology in the latter half of the century shifted the focus of 
research in cancer biology towards the specific mutations and alterations in signalling pathways 
responsible for tumorigenesis. Although it was initially thought that a set of mutations in specific 
oncogenes and tumour suppressors was sufficient to drive tumorigenesis, the spontaneous 
accumulation of such mutations in otherwise healthy tissue3 indicates that cell transformation is a 
process beyond this initial simplistic view. It has been shown that during transformation cancer 
cells undergo profound metabolic changes, given the advent of a variety of techniques to assess 
the cellular metabolome, including activation of glycolysis, altered utilization of amino acids, 
and dysregulation of mitochondrial function4. The metabolic studies in cancer also revealed 
multiple mechanisms for tumorigenesis or cancer progression driven by environmental factors 
such as high-fat diet and bioavailability of certain nutrients5-8. Discoveries during the past two 
decades, and the successful clinical implementation of imaging approaches based on the 
metabolic phenotype of some tumours have once again highlighted that changes to metabolic 
processes are required for cells to escape from their defined roles as integrated parts of a tissue 
and organ system, and become an independent clone of cells that manifests itself as malignant 
disease.  
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The most common approach to investigating and understanding tumour metabolism has been 
focusing on a set of absolute requirements for cell survival and proliferation that malignant cells 
must satisfy in order to persist within their environment. These requirements can be described in 
several ways, but a common framework is to focus on three aspects: the generation of energy to 
fuel biochemical reactions; the generation of biochemical building blocks required for cell 
growth and division via biosynthetic pathways; and the maintenance of biochemical 
homeostasis, ensuring that conditions such as redox potential are maintained within a range that 
allows cellular biochemical processes to continue9. In order to develop into an aggressive 
malignant disease, tumour cells must fulfil these requirements, along with the other well-defined 
hallmarks of cancer10. Proliferating cells tend to express glucose transporters and glycolytic 
enzymes out of proportion to the machinery required to oxidize pyruvate11, consistent with 
preferential conversion of glucose to lactate without loss of respiration. This distinction is 
important because intermediates generated by the tricarboxylic acid (TCA) cycle are precursors 
for lipids, amino acids, and nucleotides. These precursors complement precursor metabolites 
from glycolysis and other pathways and are necessary to support proliferation12. Fuels besides 
glucose also contribute to core metabolic functions of cancer cells: energy formation, biomass 
reassemble, and redox control. Glutamine is a prominent example13; however, recent work has 
revealed that a diversity of nutrients and pathways support these functions. The expanding 
metabolic repertoire of cancer cells has been reviewed extensively, with acetate and other fatty 
acids, lactate, branched chain amino acids, serine, and glycine representing some of the nutrients 
that are needed to fuel different cancers14-15. 
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Pathways downstream of oncogenes and tumour suppressors regulate cancer cell metabolism. 
Genomic alterations can also result in copy-number gains and losses of genes encoding 
metabolic enzymes, and this may induce vulnerabilities16-18. However, the extent to which 
metabolic preferences are hard-wired by the tumour genotype is less clear because many non-
genetic factors also influence tumour metabolism. As in all tissues, tumor metabolism is dictated 
by a variety of intrinsic and extrinsic factors. We need to understand how these factors are 
integrated to create metabolic dependencies. We were interested in studying PDC in prostate 
cancer because mitochondrial metabolism has been shown to be enhanced in certain types of 
tumours and certain stage of cancers to support tumour growth19-21. Cancer cells in culture have a 
different metabolic phenotype than tumours. Whereas many cancer cell lines quantitatively 
convert glucose to lactate, glucose oxidation is prevalent in tumours19, 22-24. Cultured lung cancer 
cells use glutamine to supply TCA cycle carbon, whereas lung tumours in mice prefer glucose as 
a TCA cycle fuel22-23, 25. These differences translate into altered vulnerabilities, as lung cancer 
cell lines require glutaminase for proliferation whereas tumors derived from these same cells do 
not; the converse is true for enzymes involved in glucose oxidation22. The environment can also 
affect the efficacy of drugs targeting metabolism. Metformin and other biguanides are 
mitochondrial complex I inhibitors that slow tumor growth by preventing complex I-mediated 
NAD+ regeneration26. Thus, alternative NAD+ regeneration pathways decrease complex I 
dependence and promote metformin resistance27. Lipid depletion potentiates the effect of acetyl-
coA carboxylase inhibitors in culture, but the same drugs impair lung tumor growth in vivo 
despite the presumed availability of fatty acids28. Tumors vary in the fraction of actively 
proliferating cells, which influences metabolic dependency29.  
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3.2 PDC and cancer 
Changes in mitochondrial metabolism generally provide a growth advantage in an environment 
that support cell proliferation19-23, 30-33. Given that this metabolic reprogramming is tissue 
specific, cancer cells might need to activate different gene networks including well-characterized 
oncogenes and tumour suppressors or more recently determined oncogenic enzymes in metabolic 
pathways depending on their tissue of origin34-36. The pyruvate dehydrogenases complex (PDC) 
is gatekeeper protein complex that catalyses the conversion of acetyl coenzyme A (acetyl coA) 
thereby regulating the mitochondrial metabolism. Intriguingly, normal prostate epithelial cells 
exhibit a “truncated” TCA cycle due to inhibition of aconitase needed for the production and 
secretion of a high quantity of citrate into the seminal fluid37-39. In a series of experiments carried 
out by a member of our team, we found that PDHA1, a member of the PDC complex, is 
overexpressed in prostate cancer cells.  
 
Mitochondria function as cellular energy generators, producing the fuel required to drive 
biological processes. The response of cells to mitochondrial activity or dysfunction regulates 
their survival, growth, proliferation, and differentiation. Several proteins that contain 
mitochondrial-targeting sequences (MTS) also reside in the nucleus and there is increasing 
evidence that the nuclear translocation of mitochondrial proteins represents a novel pathway by 
which mitochondria signal their status to the cell. The human pyruvate dehydrogenase complex 
(PDC) appears to translocate directly from the mitochondrial matrix to the nucleus40. This is 
supported by the observation that nuclear PDC components lack their MTS, implying prior 
processing in the mitochondrial matrix40-41. PDC links cytoplasmic glycolytic metabolism to 
mitochondrial oxidative phosphorylation by converting pyruvate to the tricarboxylic acid (TCA) 
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cycle substrate acetyl co-enzyme A (-CoA)42. It performs the same enzymatic function in the 
nucleus, providing a pool of acetyl-CoA that is used as a cofactor for histone acetylation40. 
Nuclear PDC levels are cell cycle dependent and increase in response to growth signals or the 
inhibition of oxidative phosphorylation40. Therefore, PDC coordinates mitochondrial metabolism 
with nuclear gene expression to regulate cell growth.  
 
Another theme that emerges from this focus is that the network of metabolic reactions, often 
considered separate from other cellular networks, is in fact closely integrated with key oncogenic 
signalling pathways, oncogenic mutational patterns and epigenetic regulators. Epigenetic 
reprogramming is a hallmark of many malignancies, and links between epigenetics and 
metabolism are emerging.  Epigenetic alterations can affect the metabolic profile of tumour cells, 
and also how the appropriate flow of metabolites is required to make the epigenetic 
modifications so often observed in cancer43. Interestingly, changes in metabolism are frequently 
associated with epigenetic alterations through transcriptional or post-translational modifications, 
rather than irreversible genomic events. It is therefore possible that a specific metabolic 
landscape would enable epigenetic flexibility to control gene expression40, 44-45.  
 
In our study in prostate cancer, PDC localizes in both mitochondria and nucleus. Nuclear PDC 
functions in regulating histone acetylation specifically on the promoters of lipid synthesis genes 
and thus their expression and participation in lipid synthesis to support the cancer cell 
proliferation. This epigenetically promotion of the expression of lipid synthesis genes renders 
cancer cells aberrant lipid synthesis activity rather than that in normal prostate epithelial cells to 
support high-speed proliferation. This study demonstrates the role of mitochondrial and nuclear 
 8 
PDH complex functions in regulating glucose influx of TCA cycle and controlling the diversion 
of TCA cycle intermediates. Contrast to classic ‘Warburg effect' where cancers rely 
predominantly on glycolysis and catabolic TCA cycle gets restrained, tumours could achieve 
another ‘anabolism oriented' reprogramming/axis by upregulating PDC and promoting PDC 
nuclear translocation. Nuclear PDC controls the transitory process in TCA cycle by allowing the 
short-lived entry and exit of carbon pool in mitochondria to fuel citrate synthesis and lipogenesis. 
Taking advantage of this diversion caused by nuclear PDC, the tumour cells reduce carbon 
consumption in TCA cycle thereby benefiting proliferation. PDC inactivation arrests nuclear 
PDC active cancers by abrogating both glucose influx and potential anaplerosis pathways from 
reductive carboxylation and glutaminolysis.   
 
Cancer cells have to survive under adverse environment in vivo such as lacking sufficient 
availability of oxygen and nutrient because of their outrageous growth, which would 
compromise mitochondrial function46-47. This would be the in vivo driver for the cancer cells to 
develop extra mechanism by which mitochondrial enzymes such as PDC, translocate into 
nucleus regulate and change gene expression to make the cancer cells adaptive to hostile 
environment40. These facts revealed the mechanisms by which cancer cells become more 
additive to compartmentalized PDC activity and vulnerable to PDC inhibition than their normal 
counterparts. We find that PDC inhibition by genetic or pharmacological approach, affects 
specifically in lipogenesis pathways in these cells and therefore induces strong growth arrests in 
different mouse and human xenograft tumour models without inducing global adverse effects. 
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4. Results 
4.1 Pdha1 knockout induces tumour suppression in mice and human prostate tumours. 
 
Mitochondrial metabolism is a source of energy and metabolic intermediates that serve various 
purposes, from redox homeostasis to anabolism or epigenetics1. There is an emerging association 
between increased mitochondrial metabolism and cancer pathogenesis and progression, but the 
molecular means underlying this biological process are still unknown1-10. The pyruvate 
dehydrogenase complex (PDC) is a gatekeeper multi-protein complex that catalyzes the 
conversion of pyruvate to acetyl coenzyme A (acetyl coA) thereby regulating the mitochondrial 
activity. This complex includes a major component, PDHA1, that can be dephosphorylated by the 
Pyruvate dehydrogenase phospatase (PDPs) Pdp1 and Pdp2 and phosphorylated by the pyruvate 
dehydrogenase kinases (Pdks)11-13. While dephosphorylation of PDHA1 activates the PDC, 
phosphorylation blocks its activity. In turn, we postulated that by impairing the function of PDHA1 
and the PDC we would hamper mitochondrial metabolism and ascertain its consequences in 
prostate cancer biology.  
 
We thus inactivated Pdha1, in Pten-null prostate conditional (Ptenpc-/-) mice that develop high-
grade intra-epithelial prostate tumours at an early age and invasive prostate cancer at late age14-16. 
The presence of Cre recombinase, the recombination of the Pten exon 4 and 5 and Pdha1 exon 8, 
in Ptenpc-/-; Pdha1pc-/Y prostates were verified by genotyping14,17,18 (Supplementary Fig. 1a). 
Notably, Ptenpc-/- mice develop tumours characterized by increased mRNA and/or protein levels 
of both Pdha1, Dlat, Dld and Pdp1, but not Pdp2 or Pdks, and an increased PDC activity as 
compared to normal prostates (Fig. 1a, b, Supplementary Fig. 1b and uncropped blots in 
Supplementary Fig. 12). Inactivation of Pdha1 in Ptenpc-/- tumours abrogated PDC activity and 
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induced a strong growth inhibition in all the prostate glands of mice of different ages (Fig. 1c). 
This was associated with a strong reduction in cell proliferation as shown by the decreased Ki-67 
staining and number of glands affected by invasive prostate cancer (Fig. 1d-f and Supplementary 
Fig. 1c). The strong arrest in proliferation in Ptenpc-/-; Pdha1pc-/Y tumours and Pten-/-; Pdha1-/Y 
MEFs occurred independently of senescence19 and apoptosis, that decreased when compared to 
controls (Supplementary Fig. 1d-i). Notably, Pdha1 inactivation induced growth arrest exclusively 
in Pten-/- MEFs, without altering the growth of Ptenwt MEFs (Supplementary Fig. 1g). Moreover, 
Pdha1 deletion in Pten null tumours and MEFs did not affect the levels of pAkt at Ser 473 and the 
total amount of mitochondria as indicated by the protein levels of Voltage-dependent anion 
channel 1 (Vdac1) 5 (Fig. 1a, Supplementary Fig. 1j and uncropped blots in Supplementary Fig. 
13).  
Next, we assessed the status of both PDHA1 and PDP1 in human prostate cancers. Bioinformatics 
analysis revealed that both PDHA1 and PDP1 are frequently amplified at the gene level and over-
expressed in human prostate tumours. Interestingly, PDP1 was found amplified (3/3 available 
datasets) and overexpressed (9/11 datasets) in primary prostate tumours when compared to normal 
prostate tissues whereas PDHA1 was found amplified (2/3 datasets) and overexpressed (7/13 
datasets) (Supplementary Fig. 2a-e) in metastatic when compared to primary tumours. We also 
stained PDHA1, phospho-PDHA1 and PDP1 on a tissue microarray (TMA) consisting of 128 
prostate carcinoma and normal prostate samples. Immunohistochemistry analyses revealed that 
both PDHA1 and PDP1 are frequently over-expressed in human prostate tumours and their 
expression increases in tumours with high Gleason score (Supplementary Fig. 3a-c). On the 
contrary, phospho-PDHA1 staining was found upregulated only in a small portion of cases with a 
low Gleason score (Supplementary Fig. 3a,d). Interestingly the majority of cases having either 
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high PDP1 or PDHA1 staining were negative for phospho-PDHA1 (Supplementary Fig. 3e). Three 
out of four prostate cancer cell lines exhibited increased PDC activity compared to non-
transformed PNT2C2 prostate cells (Supplementary Fig. 3f). This was associated with increased 
protein levels of both PDHA1 and PDP1 and enhanced mitochondrial oxygen consumption 
dependent on both glucose and glutamine utilization (Supplementary Fig. 3f-i and uncropped blots 
in Supplementary Fig. 14). Taken together these data demonstrate that in prostate tumours and in 
cancer cell lines the PDC is active.  
We next inactivated PDHA1 in prostate cancer cells by means of different PDHA1 shRNAs. In 
agreement with the results in the mouse model, we found that inactivation of PDC resulted in 
inhibition of cellular proliferation independently of apoptosis (Fig. 1g and Supplementary Fig. 3j,k 
and uncropped blots in Supplementary Fig. 12). We also detected, decreased mitochondrial 
respiration in cells infected with shPDHA1 when compared to control (Supplementary Fig. 3l). 
Spheres forming ability in LNCaP, 22Rv1, and PC3 was also impaired upon PDHA1 inactivation 
(Fig. 1h-j, Supplementary Fig. 3m and uncropped blots in Supplementary Fig. 14). 22Rv1 and PC3 
prostate cancer cells, infected with shPDHA1 also formed smaller tumours in vivo than controls 
(Fig. 1k, l and uncropped blots in Supplementary Fig. 12).  
Pdha1 inactivation decreases mitochondrial intermediates. 
 
Next, we performed metabolomics analysis in WT, Pdha1pc-/Y, Ptenpc-/- and Ptenpc-/-; Pdha1pc-/Y 
prostates. Ptenpc-/- tumours presented signs of increased TCA cycle as measured by increased, 
citrate, a-ketoglutarate, acetyl CoA, ATP production and NADH levels (Supplementary Fig. 4a-
d, Supplementary Table 4 and Supplementary Note). Increased extracellular lactate levels in Pten 
null MEFs also suggested increased glycolytic flux in these cells when compared to control 
(Supplementary Fig. 4e and Supplementary Note). Pdha1 inactivation in Pten null tumours and 
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MEFs resulted in decreased TCA cycle intermediates such as citrate and α-ketoglutarate and 
affected NADH/NAD+ ratio, ATP and acetyl-CoA levels (Supplementary Fig. 4a-f, 
Supplementary Table 4 and Supplementary Note). However, glycolysis and lactate production 
were not consistently affected (Supplementary Fig. 4a, e), in agreement with previous findings in 
different models20-22. Of note, oxaloacetate levels significantly increased in compound mutant 
mice, in line with a block in the cycle due to loss of acetyl-CoA production downstream PDC 
(Supplementary Fig. 4a, d and Supplementary Table 4). To determine whether Pdha1 inactivation 
induces changes in central carbon metabolism we measured stationary flux5,20 through TCA cycle 
in prostate epithelial cells derived from transgenic mice of different genotypes, using 13C-stable 
isotope labeled glucose, glutamine, and palmitate respectively. This analysis showed increased 
glucose and glutamine incorporation into citrate, fumarate, and malate in Ptenpc-/- cells when 
compared to normal prostate epithelial cells. Glucose incorporation into citrate in Ptenpc-/-; 
Pdha1pc-/Y tumor cells, decreased (~70%) when compared to Ptenpc-/- cells. Importantly, PDC 
inactivation led to compensatory oxidative glutaminolysis and to the production of acetyl-CoA 
from fatty acid β-oxidation for the reactivation of the TCA (reflected in a 30% increased citrate 
labeling from palmitate). This compensation, however, did not overcome the decreased citrate 
synthesis (Supplementary Fig. 4a and Supplementary Table 4). Surprisingly, glutaminolysis 
compensated the oxidative reactions after α-ketoglutarate to fumarate and malate until aspartate 
synthesis in TCA cycle. However, glutamine carbon pool was blocked from the reactions for 
citrate production probably due to the decreased expression of Idh1 in Ptenpc-/-; Pdha1pc-/Y when 
compared to Ptenpc-/- tumour cells (Supplementary Fig. 5d,g and Supplementary Table 5-7). 
Finally, the Pyruvate carboxylase activity did not change in response to PDHA1 loss since the 
M+3 aspartate did not increase in Ptenpc-/-; Pdha1pc-/Y when compared to Ptenpc-/- tumour cells 
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(Supplementary Fig. 4g and and Supplementary Table 5). Taken together, these data demonstrate 
that PDC inactivation reduces production of TCA intermediates and energetic yield in prostate 
tumours. 
4.2 Pdha1 knockdown induces tumour suppression by abrogating lipogenesis. 
 
Pdha1 has been long defined as a mitochondrial metabolism regulator. However, recent evidence 
demonstrates that the PDC controls the nuclear pool of acetyl-CoA thereby promoting histone 
acetylation and regulating gene expression23,24. In line with this evidence, we detected a strong 
nuclear localization of PDHA1 in Ptenpc-/- tumours and PDC activity in both the cytosol and 
nucleus of these tumour cells (see insets in Fig. 1d, Supplementary Figs. 1c and 5a,b and uncropped 
blots in Supplementary Fig. 14).  We also detected Pdha1, Dlat and Dld in the nuclear fractions of 
Ptenpc-/-  tumor cells (Supplementary Fig. 5c and uncropped blots in Supplementary Fig. 14). 
Transcriptomics followed by GSEA analysis in Ptenpc-/- and Ptenpc-/-; Pdha1pc-/Y tumours 
demonstrated that fatty acid synthesis, cholesterol biogenesis and genes controlled by the sterol 
responsive element binding factor (SREBF)25-28 were the most downregulated pathways in Ptenpc-
/-; Pdha1pc-/Y tumours (Fig. 2a).  Inactivation of Pdha1 in Ptenpc-/- tumours and shPDHA1 human 
prostate cancer cells decreased Histone H3 Lysine 9 acetylation (H3K9Ac) thereby potentially 
affecting gene expression (Fig. 2b,c and uncropped blots in Supplementary Fig. 12). Notably, two 
rate-limiting enzymes engaging fatty acid synthesis and cholesterol biogenesis, ATP Citrate Lyase 
(Acly)29,30 and Squalene Epoxidase (Sqle) 31,32 were strongly decreased in both Ptenpc-/-; Pdha1pc-
/Y tumours and shPDHA1 human prostate cancer cell lines at both protein and gene expression 
levels (Fig. 2b-f). Downregulation of ACLY in these cells was not associated with the upregulation 
of Acyl-coenzyme A synthetase short-chain family member 2 (ACSS2)33,34  (Fig. 2d,e). Genes that 
divert TCA cycle and glutamine intermediates into the lipid metabolisms22,35,36 were also 
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downregulated by PDHA1 inactivation in both mouse and human prostate tumour cells 
(Supplementary Fig. 5d-f). Importantly, acetate supplementation30 in the culture media of 22Rv1 
and PC3 infected with shPDHA1, restored global H3K9Ac, SQLE and ACLY levels (Fig. 2c). 
Chromatin immunoprecipitation (ChIP) analysis demonstrated that H3K9Ac and the binding of 
SREBF1 on the promoters of ACLY and SQLE decreased in response to the PDHA1 knockdown 
in human prostate cancer cells and this was restored by acetate supplementation (Supplementary 
Fig. 5h, i and Fig. 2g,h). Acetate supplementation restored cell growth in both Pten-/-; Pdha1-/Y 
MEFs and shPDHA1 22Rv1 and PC3 cells (Fig. 2i-k). Of note, we did not detect any changes in 
H3K9Ac on the promoter of two cell cycle regulators, E2F Transcription Factor 1 (E2F1) and 
Cyclin D1 (CCND1), demonstrating the specificity of the epigenetic regulation of PDC in cancer 
cells (Supplementary Fig. 5j,k). Interestingly, ACLY over-expression in prostate cell lines infected 
with shPDHA1 rescued the growth arrest induced by loss of PDHA1 only in cells supplemented 
with citrate (Supplementary Fig. 5l-n and uncropped blots in Supplementary Fig. 14) in agreement 
with previous data30. 
           We next performed a direct measurement of lipid species in mouse prostate tumours and 
human prostate cancer cell lines depleted of PDHA1. Of note, the majority of lipid species, 
including cholesterol ester were decreased in Ptenpc-/-; Pdha1pc-/Y when compared to Ptenpc-/- 
tumours and in shPDHA1 22Rv1 and PC3 cells when compared to control cells (Supplementary 
Fig. 6, Supplementary Table 8-11 and Supplementary Note). 14C tracking experiments in sh-
PDHA1 22Rv1 and PC3 cells demonstrated that glucose and glutamine incorporation into lipids 
and cholesterol (Supplementary Fig. 7a-e and Supplementary Note) were strongly affected when 
compared to controls whereas glucose and glutamine incorporation into proteins, remained 
unchanged (Supplementary Fig. 7f,g and Supplementary Note). PDHA1 knockdown did not affect 
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glucose uptake but induced a slight increase of glutamine uptake (Supplementary Fig. 7h, i and 
Supplementary Note). In agreement with these findings lipid droplets, a known readout of lipid 
production5,37, were strongly reduced in both mouse and human xenograft tumours upon PDHA1 
inactivation (Fig. 3a-d and Supplementary Fig. 7j-o). To assess whether lipid metabolism is 
affected by PDHA1 inactivation, we cultured sh-PDHA1 22Rv1 and PC3 cells in both the presence 
and absence of fatty acids and we found that fatty acids fully rescued the growth arrest induced by 
the PDHA1 knockdown. This was associated with the restoration of lipid droplets in the same cells 
(Fig. 3e,f and Supplementary Note). Rescue of proliferation upon fatty acid supplementation 
occurs independently by H3K9 acetylation and reactivation of the expression of ACLY and SQLE 
(Supplementary Fig. 7p and uncropped blots in Supplementary Fig. 15). This data suggests that 
fatty acids were directly incorporated into lipids. Collectively, these data demonstrate that PDC 
activity is required for the proliferation of mouse and human prostate tumour cells and that 
inactivation of PDC drives tumour growth inhibition by affecting histone acetylation and the 
expression of genes controlling lipid metabolism.  
4.3 Nuclear PDC regulates the expression of lipid biosynthesis genes independently of 
mitochondrial PDC. 
Cellular compartmentalization allows cells to carry out different metabolic reactions at the same 
time, and pathological protein compartmentalization is associated with cancer38. We, therefore, 
dissected the role of nuclear and cytosolic PDC in prostate cancer, by expressing nuclear export 
signal (NES) and/or nuclear localization signal (NLS) fused PDHA1 vectors in prostate cancer cell 
lines previously infected with (shRNA) and without PDHA1 (shPDHA1) (Fig. 4a, uncropped blots 
in Supplementary Fig. 13 and Supplementary Fig. 8a). NES-PDHA1 and NLS-PDHA1 constructs 
were engineered as shPDHA1 resistant vectors. Expressions of these vectors in 22Rv1 cells did 
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not affect SREBF1 maturation and nuclear translocation (Supplementary Fig. 8a). Restoration of 
NLS-PDHA1 in sh-PDHA1 cells recovered H3K9Ac and the expression of fatty acid synthesis 
genes (Fig. 4b-d, Supplementary Fig. 8b for the full panel and uncropped blots in Supplementary 
Fig. 13,15), but did not rescue citrate levels, lipids content and cell growth both in vitro and in vivo 
(Fig. 4e-h and Supplementary Fig. 8c-g). In contrast, overexpression of both NES-PDHA1 and 
NLS-PDHA1 restored lipid synthesis genes, citrate levels, lipids content and cell growth (Fig. 4b-
h and Supplementary Fig. 8b-g). Interestingly, the selective ACLY inhibitor, SB-204990 partially 
decreased H3K9 acetylation in prostate cancer cells with high PDC activity and SB-204990 did 
not further increase the growth arrest in prostate cancer cells infected with a shRNA against 
PDHA1 (Supplementary Fig. 8h-j and uncropped blots in Supplementary Fig. 15). These data 
demonstrate that PDC can directly contribute to histone acetylation, independently by the 
regulation of ACLY30. These experiments reveal that nuclear PDC regulates the expression of lipid 
synthesis gene in an autonomous manner and both nuclear and cytosolic PDHA1 are needed for 
the proliferation of prostate cancer cells.  
4.4 Nuclear PDC regulates fatty acid synthesis in presence of mitochondrial citrate. 
 
Consistently with these findings, we proved that overexpression of NLS-PDHA1 rescued growth 
arrest and lipid synthesis in cells cultured in the presence of citrate (Fig. 5a, b and Supplementary 
Fig. 9a for the whole panel). To validate these findings using an additional system, we 
overexpressed PDK1 in prostate cancer cells. Previous evidence demonstrates that PDK1 
overexpression suppresses mitochondrial metabolism decreasing the intracellular levels of citrate 
without halting the nuclear function of PDC23,39-41. In line with this evidence overexpression of 
PDK did not promote phosphorylation of nuclear PDHA1 (Supplementary Fig. 9b and uncropped 
blots in Supplementary Fig. 15). Overexpression of PDK1 in 22Rv1 cells decreased citrate levels 
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and slightly suppresses cancer cell proliferation both in vitro and in vivo (Fig. 5c-e and 
Supplementary Fig. 8c-e). However, it did not decrease histone acetylation and expression of fatty 
acid synthesis genes (Fig. 5f, uncropped blots in Supplementary Fig. 13 and Supplementary Fig. 
9b). In contrast, concomitant inactivation of PDHA1 and overexpression of PDK1 decreased 
citrate level, histone acetylation and lipids content thereby suppressing tumourigenesis of a greater 
extent than in cells infected with PDK1 alone (Fig. 5c-f and Supplementary Fig. 9c-e). Taken 
together, these results demonstrate that both mitochondrial and nuclear PDC is required for 
prostate tumour growth. 
4.5 Pharmacological inhibition of PDHA1 arrests mouse and human prostate tumours. 
  
Given that prostate cancer relies on PDC for proliferation we assessed whether pharmacological 
inhibition of PDHA1 could also block tumourigenesis in Ptenpc-/- tumours and human xenograft 
models of prostate cancer. We reasoned that a compound that could affect both the mitochondrial 
and nuclear function of PDC could be effective in blocking prostate cancer. To this extent, we took 
advantage of 3-fluoropyruvate (3-FP), a competitive inhibitor of the PDHA142-45. Computer 
simulations confirmed that 3-FP and pyruvate bind to PDHA1 with similar affinity 
(Supplementary Fig. 10a, b and Supplementary Note). To assess the specificity of 3-FP for the 
PDC, cell lysates treated with 3-FP were incubated in presence or absence of pyruvate. 3-FP 
decreased the activity of PDC and this was reversed by adding pyruvate in a dose dependent 
manner to the reaction buffer (Supplementary Fig. 10c). 3-FP administered by intraperitoneal 
injection in Ptenpc-/- mice inhibited the PDC activity in vivo in absence of systemic toxicity and 
induced a strong decrease of tumour cells proliferation as demonstrated by the reduced tumour 
size, tumour invasiveness and Ki-67 staining (Supplementary Fig. 10d-j). Importantly, 3-FP 
inhibited PDC both in the nucleus and the cytosol of prostate tumour cells and decreased H3K9Ac, 
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Acly and Sqle levels in vivo at both protein and mRNA levels (Supplementary Fig. 10k-m and 
uncropped blots in Supplementary Fig. 15). Metabolomics analysis via LC-MS/MS46 confirmed 
that 3-FP strongly affected pyruvate metabolism and TCA cycle (Supplementary Fig. 11a). 
Finally, lipids droplet staining showed a decreased percentage of the number, size and intensity of 
lipid bodies in Ptenpc-/- tumours treated with 3-FP (Supplementary Fig. 11b-e). 3-FP treatment 
blocked the proliferation of different human prostate cancer cells and this was associated with a 
decreased PDC activity (Supplementary Fig. 11f, g). Finally, 3-FP treatment decreased the 
proliferation of different human prostate cancer xenografts (LNCaP, 22Rv1 and PC3) promoting 
long-lasting anti-tumour responses in vivo (Supplementary Fig. 11h-j). Taken together these data 
suggest that pharmacological inactivation of PDC hampers prostate cancer progression. 
 
5. Discussion 
Whether the PDC acts as an oncogene or tumour suppressor in cancer is still under 
debate19,22,23,39,40,47-49. A previous report shows that reduction in PDC activity through 
overexpression of PDK1 in melanoma cells promote tumour cell proliferation by enhancing 
glycolysis and reductive carboxylation19. In this and other models, activation of PDC by 
dichloroacetate promoted tumour suppression19,47. Our data provide a new angle and demonstrate 
that the subunits of the PDC such as PDHA1 and PDP1 are amplified and overexpressed at both 
gene and protein levels and that the PDC is active in prostate cancer. In line with this evidence, 
we demonstrate that inactivation of PDHA1 hampers prostate cancer progression in vivo in both 
mouse and human prostate cancer models. These findings are in agreement with recent studies 
demonstrating that tumor cells, in vivo, increased glucose oxidation via PDC. PDHA1 inactivation 
in non-small lung cells cancer (NSCLC) xenografts resulted in a decreased tumor formation 
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capacity. An increased TCA cycle via PDC was also observed in poorly perfused tumours areas 
of patients affected by NSCLC9,10,50. These data, together with our data in prostate cancer, 
challenged the notion that tumours switch from glucose derived oxidative metabolism to aerobic 
glycolysis to support their growth6. However, the mechanisms by which tumour cells in vivo 
become addicted to PDC-mediated mitochondrial metabolisms still remain unknown. As 
suggested by previous studies this may be explained by the genetic background of the tumours, a 
difference in tissue requirements or in the composition of the tumour microenvironment10. 
Intriguingly normal prostate epithelial cells exhibit a “truncated” TCA cycle due to inhibition of 
aconitase needed for the production and secretion of a high quantity of citrate into the seminal 
fluid51-53. Therefore, it is not surprising that prostate cancer relies on mitochondrial metabolism 
more than other tumour types.  
             Our results reveal that in order to support prostate cancer growth the PDC must be 
functional in both mitochondria and the nucleus of cancer cells. Mitochondrial PDC function is 
not sufficient to support lipid biosynthesis in tumour cells since nuclear PDC regulates the 
transcription of the enzymes that convert cytosolic citrate into acetyl-coA and fatty acids 
(Supplementary Fig. 11k, l). This compartmentalization allows the mitochondrial production of 
citrate in the cytosol and the expression of enzymes required for de novo lipid biosynthesis. Prior 
studies demonstrate that prostate cancer also benefits of enhanced glycolytic metabolism. 
However, these aggressive glycolytic tumour cells retain an active glucose-derived lipid 
biosynthesis54, thus in line with the results presented herein. 
Our findings also hold important implications for cancer therapy and pave the way for the targeting 
of the nuclear function of PDC to eradicate prostate cancer. This may be achieved in the future as 
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shown in this paper by using pyruvate analogs or alternatively by developing small molecule 
inhibitors of PDHA1.   
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Figure 1 
Pdha1 knockout induces tumour suppression in mice and human prostate tumours. 
(a) Western blot analysis of indicated proteins in wild type, Pdha1pc-/Y, Ptenpc-/- and Ptenpc-/-; Pdha1pc-/Y prostates 
and tumours (n=3, independent prostate samples). Uncropped images are in Supplementary Figure 12. (b) Upper 
panel, PDC activity measurement in wild type, Pdha1pc-/Y, Ptenpc-/- and Ptenpc-/-; Pdha1pc-/Y prostates and tumours 
(n=3, independent prostate samples). Lower panel, Quantification of indicated proteins normalized to wild type 
tissues in indicated prostate tumours in (a) (n=3, independent prostate samples). (c) Comparison of anterior 
prostate (AP) lobe volumes (mm3, 2 independent lobes per animal are presented) from male of indicated ages and 
genotypes between wild type, Pdha1pc-/Y, Ptenpc-/- and Ptenpc-/-; Pdha1pc-/Y prostate and tumours (N, the number of 
mice of indicated ages). Inset is the representative image of anterior prostate lobes in the panel. (d) Representative 
micrographs in histopathological analysis (haematoxylin/eosin staining and indicated proteins) of anterior 
prostates (AP) in Pdha1pc-/Y, Ptenpc-/- and Ptenpc-/-; Pdha1pc-/Y prostate tissues from 12 weeks old male mice (n=3) 
(Scale bar represents 50 μm, insets are regions shown in higher magnification, see also Supplementary Fig. 1c 
for all the genotypes and images of lower magnification). (e,f) Quantification of the percentage of Ki-67 positive 
cells (e) and invasive prostate glands (f) in prostates from mice of indicated genotypes at different ages (N, 
number of mice of indicated ages). (g) Relative cell number quantification by crystal violet staining in the 
indicated prostate cancer cell lines infected with shPDHA1 or scramble control. Data is normalized to shRNA 
control. PDHA1 inhibition validated by western blot analysis using two different shPDHA1 was shown in the 
inset of the panel. Uncropped images are in Supplementary Figure 12. (n=3, independent cell cultures). (h) 
Spheroid Formation Assays in LNCaP, 22Rv1 and PC3 cells infected with doxycycline-induced Tripz-shPDHA1 
or scramble control (n=3, independent cell cultures). Scale bar represents 50 µm. (i,j) Quantification of spheroid 
diameter (i) and spheroid number per 500 cells (j) in LNCaP, 22Rv1 and PC3 cells infected with doxycycline-
induced Tripz-shPDHA1 or scramble Tripz-shRNA control (n=3, independent cell cultures). (k,l) Evaluation of 
tumour formation in xenotransplantation experiments of 22Rv1 (k) and PC3 (l) cells infected with indicated 
shPDHA1 or scramble shRNA control. The knockdown of PDHA1 in 22Rv1 and PC3 xenograft tumours is 
validated by western blot in the inset of panel (k). Uncropped images are in Supplementary Figure 12. (n=6 
animals; 12 independent tumour samples). Error bars indicate s.e.m. **P < 0.01; ***P < 0.001. n.s, not 
significant. 
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Figure 2 
Pdha1 inactivation induces tumour suppression by down-regulating lipogenic genes. 
(a) Gene expression profile analysis based on metabolic pathway datasets (GOCC, Gene Ontology Cellular 
Component; KEGG, Kyoto Encyclopaedia of Genes and Genomes; GOBO, Gene expression-based Outcome; 
GOMF, Gene Ontology Molecular Function; HumanCyc; Reactome) in Ptenpc-/-; Pdha1pc-/Y tumours versus 
Ptenpc-/- tumours. Dotted line indicates P=0.05 (n=3). (b) Western blot analysis of indicated proteins in wild type, 
Pdha1pc-/Y, Ptenpc-/- and Ptenpc-/-; Pdha1pc-/Y prostates and tumours. Uncropped images are in Supplementary 
Figure 12. (n=3, independent prostate samples). (c) Western blot analysis of indicated proteins in 22Rv1 cells 
infected with doxycycline-induced Tripz-shPDHA1 or scramble control and treated with 100 μM acetate or 
vehicle over a 6-day period. Uncropped images are in Supplementary Figure 12. (n=3, independent cell cultures). 
(d) Upper panel, GSEA of SREBF target genes in Ptenpc-/-; Pdha1pc-/Y versus Ptenpc-/- prostate tumours. 
Normalized enriched scores (NES) are presented. Data are mean ± standard deviation (s.d.). Lower panel, 
quantitative real time-PCR analysis of mRNA expression of indicated SREBFs and target genes and genes in 
acetyl CoA compensatory pathways in mouse prostate and tumours the indicated genotypes (n=3). (e) 
Quantitative real time-PCR analysis of mRNA expression of indicated SREBFs and target genes and genes in 
acetyl coA compensatory pathways in 22Rv1 cells infected with shPDHA1 and scramble shRNA control (n=3, 
independent cell cultures). (f) Quantitative RT-PCR analysis of ACLY and SQLE in 22Rv1 cells infected with 
doxycycline-induced Tripz-shPDHA1 or scramble control and treated with acetate (100 µM) or vehicle for 6 days 
(n=3, independent cell cultures). (g,h) Chromatin immunoprecipitation analysis showing the binding of SREBF1 
and H3K9Ac on the promoters of ACLY (g) and SQLE (h) in 22Rv1 and PC3 cells infected with doxycycline-
induced Tripz-shPDHA1 or scramble control and treated with 100 μM acetate or vehicle over a 6-day period 
(n=3, independent cell cultures). (i-k) Relative cell number quantification by crystal violet staining of Pten-/- and 
Pten-/-; Pdha1-/Y MEFs (i) and human cancer cells 22Rv1 and PC3 cells infected with doxycycline-induced Tripz-
shPDHA1 or scramble control. (j,k) and treated with acetate (100 µM) or vehicle over a 6-day period (n=3, 
independent cell cultures). Error bars indicate s.e.m. *P < 0.05; **P < 0.01; ***P < 0.001. n.s, not significant. 
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Figure 3 
Pdha1 knockdown induces tumour suppression by abrogating lipogenesis. 
(a,b) Representative confocal images (a) and quantification of average lipid droplets per cell (Lipidtox, red) (b) 
in the indicated genotypes in Ptenpc-/-; Pdha1pc-/Y versus Ptenpc-/- prostate tumours. DAPI, blue. (n=3 mice, Scale 
bar: 20 µm, 1 tumour per mouse, 5 fields acquired). (c,d) Representative confocal images (c) and quantification 
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of average lipid droplets per cell (Lipidtox, red) (d) in 22Rv1 and PC3 shPDHA1 and shRNA xenograft tumours. 
DAPI, blue. (n=3 mice, Scale bar represents 20 µm, 1 tumour per mouse, 5 fields acquired). (e,f) Relative cell 
number quantification by crystal violet staining (e) and quantification of lipid droplets by average lipid droplet 
per cell (f) in 22Rv1 and PC3 cells infected with a shPDHA1 and scramble shRNA control and treated with 
exogenous fatty acids in fatty acid free media; oleate (25 μM), palmitate (25 μM) or a combination of these two 
were used(n=3, independent cell cultures). Error bars indicate s.e.m. *P < 0.05; **P < 0.01; ***P < 0.001. n.s, 
not significant. 
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Figure 4 
Nuclear PDC regulates the expression of lipid biosynthesis genes independently of mitochondrial PDC. 
(a) Western blot analysis of indicated proteins in nuclear and cytoplasmic fractions of shPDHA1 22Rv1 cells 
infected with NES-PDHA1 and NLS-PDHA1 alone or in combination. Uncropped images are in Supplementary 
Figure 13. (n=3, independent cell cultures). (b) Western blot analysis of indicated proteins in shPDHA1 22Rv1 
cells infected NES-PDHA1 and NLS-PDHA1 alone or in combination (see full panel in Supplementary Fig. 
5b). Uncropped images are in Supplementary Figure 13. (n=3, independent cell cultures). (c-e) Quantitative 
real-time PCR analysis of mRNA expression for ACLY (c) and SQLE (d) and determination of citrate levels (e) 
in shRNA control and shPDHA1 22Rv1 and PC3 infected with NES-PDHA1, NLS-PDHA1 alone or in 
combination (n=3, independent cell cultures). (f) Representative confocal images and quantification of lipid 
droplets (average lipid droplets per cell) in shPDHA1 22Rv1 infected with NES-PDHA1, NLS-PDHA1 alone or 
in combination (n=3, independent cell cultures, Scale bar represents 10 µm, 5 fields acquired for each group). 
(g) Upper panel, representative images of crystal violet staining of shPDHA1 22Rv1 infected with infected with 
NES-PDHA1, NLS-PDHA1 alone or in combination (n=3, independent cell cultures). Lower panel, relative cell 
number quantification by crystal violet staining in shRNA control and shPDHA1 22Rv1 and PC3 infected with 
NES-PDHA1, NLS-PDHA1 alone or in combination (n=3, independent cell cultures).  (h) Upper panel, 
representative micrographs in histopathological analysis of Ki-67 of these xenograft tumours. Lower panel, 
evaluation of tumour formation in xenotransplantation experiments of shPDHA1 22Rv1 infected with NES-
PDHA1, NLS-PDHA1 alone or in combination (n=6 animals; 12 injections, Scale bar represents 50 µm, also 
see Supplementary Fig. 7d for the full panel). Error bars indicate s.e.m. *P < 0.05; **P < 0.01; ***P < 0.001. 
n.s, not significant. 
 29 
 
 30 
Figure 5 
Nuclear PDC regulates fatty acid synthesis in presence of mitochondrial citrate. 
(a,b) Relative cell number quantification by crystal violet (a, also see full panel in Supplementary Fig. 8a) and 
quantification by confocal microscopy of average lipid droplets per cell (b) in shPDHA1 22Rv1 and PC3 cells 
infected with NES-PDHA1, NLS-PDHA1 alone or in combination and treated with citrate (100 µM) or vehicle 
for 6 days (n=3, independent cell cultures). (c) Upper panel, Representative confocal images, and quantification 
of average lipid droplets per cell, in xenograft tumours from shRNA control and shPDHA1 22Rv1 cells infected 
with PDK1 or empty vector. Lower panel, Evaluation of tumour formation in xenotransplantation experiments in 
shRNA control and shPDHA1 22Rv1 cells infected with PDK1 or empty vector (n=6 animals; 12 injections, 5 
fields acquired for each group and Scale Bar represents 20 μm). (d) Upper panel, representative immune-
histochemistry micrographs for Ki-67 staining in tumours of the indicated genotypes. (n=6 animals; 12 injections, 
5 fields acquired for each group and scale bar represents 50 μm). Lower panel, quantification of the percentage 
of Ki-67 positive cells in different tumour genotypes (n=6 animals; 12 injections, 5 fields acquired for each 
group).  (e,f) Determination of citrate levels (e) and western blot analysis of indicated proteins (f) in xenograft 
tumours from shRNA control and shPDHA1 22Rv1 cells infected with PDK1 or empty vector. Uncropped images 
are in Supplementary Figure 13. (n=6, independent tumour samples). Error bars indicate s.e.m. *P < 0.05; 
**P < 0.01; ***P < 0.001. n.s, not significant. 
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Supplementary Fig. 1 
Pdha1 knockout induces tumour suppression in mice prostate tumours. 
(a) The efficiency of Probasin-Cre4 (Pb-Cre4) mediated recombination of the PtenloxP/loxP and Pdha1loxP/Y allele 
as scored by PCR amplification in wild type, Pdha1pc-/Y, Ptenpc-/- and Ptenpc-/-; Pdha1pc-/Y prostates and tumours. 
(n=3, independent prostate samples) (b) Quantitative real time-PCR analysis of mRNA expression of Pdha1, 
Dlat, Dld and Pdha1 regulator genes in Ptenpc-/-  prostate tumours versus wild type prostate tissues (n=3, 
independent prostate samples). (c-d) Representative micrographs in histopathological analysis 
(haematoxylin/eosin staining and indicated proteins) of anterior prostates (AP) (n=3, independent prostate 
samples, 5 fields for each group, scale bar represents 50 µm) (c) and representative micrographs of senescence 
associated β-Gal (SA- β-Gal) staining (n=3 independent prostate samples, 5 fields for each group and scale bar 
represents 50 µm) (d)  in wild type, Pdha1pc-/Y, Ptenpc-/- and Ptenpc-/-; Pdha1pc-/Y prostates and tumours. (e, f) 
Apoptosis analysis by cleaved caspase 3 (e) and quantification of the percentage of cleaved caspase 3 positive 
cells (f) of anterior prostates (AP) in 12-week-old Ptenpc-/- and Ptenpc-/-; Pdha1pc-/Y tumours (N: small necrotic 
foci, n=3 mice, 5 fields for each group and scale bar represents 50 µm). (g-j) Relative cell number quantification 
by crystal violet staining (g), senescence associated β-Gal (SA-β-Gal) staining (h), cellular apoptosis assay by 
Annexin V staining (i) and western blot analysis of indicated proteins (j) of wild type, Pdha1-/-, Pten-/- and Pten-
/-; Pdha1-/-  MEFs on 6th day after retroviral Cre infection and selection. Uncropped images are in Supplementary 
Figure 13. (n=3, independent cell cultures). Error bars indicate s.e.m. *P < 0.05; **P < 0.01. n.s, not significant. 
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Supplementary Fig. 2 
PDHA1 and PDP1 get frequently amplified and overexpressed in human prostate cancer. 
(a-c) The number of datasets (a), bar graph of amplification or overexpression of these datasets and underlined 
are comparisons (7 out of 24) where both genes are gained/amplified or overexpressed (b) and sample number in 
indicated comparison and P value (c) from Oncomine or cBioPortal cohorts by which significant copy-number 
gain or amplifications (DNA) or overexpression (mRNA) exits when the following comparisons are computed: 
i, DNA, primary versus normal germline; ii, DNA, metastasis versus primary; iii, DNA, metastasis versus normal 
germline; iv, mRNA, primary versus normal prostate glands and v, mRNA, metastasis versus primary. Significant 
overexpression or copy number values are computed using T-test (two-tailed, P<0.05, in ii, iv and v), or using 
GISTIC or RAE (in i and iii). (d,e) Alteration frequency analysis of PDHA1 (d) and PDP1 (e) from 11 studies 
on prostate cancers available on cBioPortal. 
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Supplementary Fig. 3 
PDHA1 and PDP1 get overexpressed in human prostate cancer cell lines and tumours. 
(a) Representative immune-histochemical staining for PDHA1, phospho-PDHA1293 and PDP1 in a prostate 
cancer tissue microarray (TMA) of 128 patients (5 fields acquired for each sample, PIN indicates prostatic 
intraepithelial neoplasia, HGPIN indicates high-grade prostatic intraepithelial neoplasia, PCA indicates invasive 
prostate cancer, and scale bar represents 50 µm) (b-d) Evaluation and quantification of immune-histochemical 
staining for PDHA1 (b), PDP1 (c) and phospho-PDHA1293(d) in human tumour samples in panel (a). (e) 
Quantification of immune-histochemical staining of phospho-PDHA1293 in PDHA1 or PDP1 moderate/high 
expression samples. The gray frames highlighted the numbers of PDHA1 or PDP1 moderate/high expression 
samples (f) Upper panel, PDC activity measurements in prostate cancer cells using a standard quantitative dipstick 
assay (n=3, independent cell cultures). Lower panel, western blot analysis of indicated proteins in prostate cancer 
cell lines. Uncropped images are in Supplementary Figure 14. (n=3, independent cell cultures). (g) Quantification 
of western blots for PDHA1 and PDP1 in panel (f) (n=3, independent cell cultures). (h) Mitochondrial oxygen 
consumption rate analysis of the indicated prostate cancer cell lines (n=3, independent cell cultures). (i) 
Mitochondrial oxygen consumption rate analysis of 22Rv1 prostate cancer cell line in the media supplemented 
with glucose (11 mM), glutamine (2 mM) or a combination of these two (n=3, independent cell cultures). (j,k) 
Cellular proliferation assay by BrdU staining (j) and cellular apoptosis assay by Annexin V staining (k) in cell 
lines infected with indicated shPDHA1 or scramble shRNA control (n=3, independent cell cultures). (l) 
Mitochondrial oxygen consumption rate analysis of 22Rv1 prostate cancer cell line infected with shPDHA1 or 
scramble control. (n=3, independent cell cultures). (m) Western blot analysis of PDHA1 in cell lines infected 
with doxycycline-induced Tripz-shPDHA1 or scramble control in Fig. 1 panel (h-j). Uncropped images are in 
Supplementary Figure 14. (n=3, independent cell cultures). Error bars indicate s.e.m. *P < 0.05; **P < 0.01. n.s, 
not significant. 
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Supplementary Fig. 4 
Pdha1 inactivation decreases mitochondrial intermediates. 
(a) Representative intermediates level in glycolysis and tricarboxylic acid (TCA) cycle of wild type, Pdha1pc-/Y, 
Ptenpc-/- and Ptenpc-/-; Pdha1pc-/Y prostates and tumours (n=3, independent prostate samples). (b-d) 
Determination of relative NADH/NAD+ ratio (b), ATP/ADP ratio (c) and acetyl coA levels (d) in wild type, 
Pdha1pc-/Y, Ptenpc-/- and Ptenpc-/-; Pdha1pc-/Y prostates and tumours (n=3, independent prostate samples). (e,f) 
Determination of extracellular lactate levels (e) and acetyl coA levels (f) in wild type, Pdha1-/-, Pten-/- and Pten-
/-; Pdha1-/-  MEFs (n=3, independent cell cultures). (g) Representative data depict abundance of selected labelled 
metabolites from [U-13C6]-Glucose, [U-13C5]-Glutamine and [U-13C16]-palmitate respectively in mouse prostate 
epithelial cells derived from wild type, Pdha1pc-/Y, Ptenpc-/- and Ptenpc-/-; Pdha1pc-/Y prostates and tumours. 
Glucose, glutamine and Palmitate metabolism profiles were presented as actual intensities. (n=3, independent 
prostate samples). Error bars indicate s.e.m. *P < 0.05; **P < 0.01; ***P < 0.001. n.s, not significant. 
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Supplementary Fig. 5 
PDC controls histone acetylation and the expression of genes that link reductive carboxylation to 
lipogenesis. 
(a) Upper left panel, PDC activity measurements of nuclear and cytoplasmic fractions of Ptenpc-/- tumours loaded 
in different amount in standard dipstick assay.  Upper right panel, fractionation was validated by western blot 
analysis for the indicated proteins. Lower panel, quantification of the optical density of dipstick bands from the 
upper left panel. The dash line represents the amount of lysate (80 μg) used in all the measurements performed 
in the paper, which fall in the linear range of the assay (n=3, independent prostate samples). Uncropped images 
are in Supplementary Figure 14. (b) PDC activity measurements in nuclear fractions of Ptenpc-/-  tumour cells 
incubated in presence of pyruvate at the indicated concentration in the activity buffer (n=3, independent prostate 
samples). (c) Western blot analysis of indicated proteins in nuclear and cytoplasmic fractions in wild type, 
Pdha1pc-/Y, Ptenpc-/- and Ptenpc-/-; Pdha1pc-/Y prostates and tumours (n=3, independent prostate samples). 
Uncropped images are in Supplementary Figure 14. (d-f) Quantitative real time-PCR analysis of mRNA 
expression for Isocitrate dehydrogenase isozymes in mouse prostate tissues of indicated genotypes (n=3, 
independent prostate samples) (d) and 22Rv1(e) and PC3(f) cells infected with shPDHA1 or scramble shRNA 
control (n=3, independent cell cultures). (g) Schematic overview of Pyruvate dehydrogenase, tricarboxylic acid 
cycle, β-oxidation, glutaminolysis and lipogenesis pathways (The green represents down-regulated genes). (h,i) 
Schematic overview of primer sites of for H3K9Ac and the binding of SREBP1 detection on the ACLY (h) and 
SQLE (i) promoters. H3K27Ac profile (UCSC Genome Browser on Human Feb. 2009 (GRCh37/hg19) 
Assembly) was used for prediction of H3K9Ac status. (j,k) Chromatin immunoprecipitation analysis of H3K9Ac 
levels on the promoter of E2F1 (j) and CCND1 (k) in 22Rv1 and PC3 cells infected with doxycycline-induced 
Tripz-shPDHA1 or scramble control (n=3, independent cell cultures). (l) Western blot analysis of indicated 
proteins in shPDHA1 or scramble control 22Rv1 cells infected with ACLY over-expressing lentivirus vector or 
empty vector control (EV) and treated with 100 μM citrate or vehicle over a 9-day period. Uncropped images are 
in Supplementary Figure 15.  (n=3, independent cell cultures). (m,n) Relative cell number quantification by 
crystal violet staining of shPDHA1 or scramble control 22Rv1 (m) and PC3 (n)  cells infected with ACLY over-
expressing lentivirus vector or empty vector control (EV) and treated with 100 μM citrate or vehicle over a 9-day 
period (n=3, independent cell cultures). Error bars indicate s.e.m. *P < 0.05; **P < 0.01; n.s, not significant. 
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Supplementary Fig. 6 
PDC inactivation reduces lipid and cholesterol levels in prostate cancer. 
(a) A scatterplot Log10 intensity of Ptenpc-/-; Pdha1pc-/Y tumours vs. Log2 Ratio of Ptenpc-/-; Pdha1pc-/Y tumours 
versus Ptenpc-/- tumours showing the distribution of 2,062 identified lipid ions (blue dots) including cholesterol 
esters (red dots) via LipidSearch from lipids extracted from three biological replicates of Ptenpc-/-; Pdha1pc-/Y 
tumours and Ptenpc-/- tumours tissue extracts (~5 mg injected). ChE represents Cholesteryl esters (n=3, 
independent prostate samples) (b,c) The relative abundance of lipid species by intensity in wild type, Pdha1pc-/Y, 
Ptenpc-/- and Ptenpc-/-; Pdha1pc-/Y prostates and tumours (n=3, independent prostate samples). The top three lipids 
in fold change between Ptenpc-/- tumours and wild type prostate were labeled as red. The lipid classes and 
abbreviations: Ceramide (Cer), Cholesteryl ester (ChE), Diradylglycerolipids (DG)，lysophosphatidylcholine 
(LPC), lysophosphatidylethanolamine (LPE), lysylphosphatidylglycerol (LPG), lysophosphatidylinositol (LPI), 
lysophosphatidylserine (LPS), lysodimethylphosphatidylethanolamine (LdMeP), Monoradylglycerolipids (MG), 
(O-acyl)-omega-hydroxy fatty acids (OAHFA), phosphatidic acid (PA), phosphatidylcholine (PC), 
phosphatidylethanolamine (PE), Phosphatidylglycerol (PG), phosphatidylinositol (PI), phosphomonoesters 
(PMe), phosphatidylserine (PS), Sphingomyelin (SM), Triglyceride (TG), dimethylphosphatidylethanolamine 
(dMePE). (d-f) The relative abundance of lysylphosphatidylglycerol (LPG) (d), phosphomonoesters (PMe) (e), 
Cholesteryl ester (ChE) (f) species in wild type, Pdha1pc-/Y, Ptenpc-/- and Ptenpc-/-; Pdha1pc-/Y prostates and tumours 
(n=3, independent prostate samples). (g,h) Significantly changed levels of cholesterol (COH) and 14 Cholesteryl 
esters (CE) in 22Rv1 (g) and PC3 (h) cells infected with two shPDHA1 or a scramble shRNA control (n=3, 
independent cell cultures). The Variable Importance in Projection (VIP) scores depicting the top-ranked 
metabolites that contributed to the separation of prostate cancer cells infected with two shPDHA1 and a scramble 
control. A value of VIP score greater than 1 suggests actual contribution of the considered lipid to the group 
separation. The coloured boxes on the right indicate the relative concentrations of the corresponding metabolite 
in each group under study. The scale bar depicts the relative metabolite levels (red, high abundance; blue, low 
abundance). Error bars indicate s.e.m. *P < 0.05; n.s, not significant. 
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Supplementary Fig. 7 
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Pdha1 inactivation mainly affects de novo lipid synthesis in prostate cancer. 
(a) Scheme of radioactive 14C tracing using D- [U-14C6]-Glucose (14C-Glucose) and L-[U-14C5]-Glutamine (14C-
Glutamine) measuring glucose and glutamine incorporation into lipids.  (b,c) Radioactive tracing using 14C- 
glucose (b) and 14C-glutamine (c) for de novo lipogenesis in 22Rv1 and PC3 cells infected with two shPDHA1 
and scramble shRNA control (n=3, independent cell cultures). (d,e) Radioactive tracing using 14C- glucose (d) 
and 14C-glutamine (e) for de novo cholesterol synthesis in 22Rv1 and PC3 cells infected with two shPDHA1 and 
scramble shRNA control (n=3, independent cell cultures). (f,g)Radioactive tracing using 14C- glucose (d) and 
14C-glutamine (e) in protein synthesis in 22Rv1 and PC3 prostate cancer cell line infected with shPDHA1 or 
scramble shRNA control (n=3, independent cell cultures). (h,i) Glucose uptake (h) and glutamine uptake (i) 
analysis in 22Rv1 and PC3 cells infected with shPDHA1 or scramble shRNA control (n=3, independent cell 
cultures). (j-l) Confocal microscopy quantification of intra-tumour lipid droplets by average lipid droplets total 
fluorescence (a.u.) (j) average lipid droplets per mm2 (k) and average lipid droplet area in µm2 (l) in the indicated 
genotypes (n=3 independent prostate samples, 5 fields acquired for each group) in Ptenpc-/-; Pdha1pc-/Y versus 
Ptenpc-/- prostate tumours. DAPI, blue. Scale bar: 20 µm (n=3 independent prostate samples, 5 fields acquired). 
(m-o) Confocal microscopy quantification of intra-tumour lipid droplets by average lipid droplet total 
fluorescence (a.u.) (m) average lipid droplets per mm2 (n) and average lipid droplet area in µm2 (o) in 22Rv1 and 
PC3 shPDHA1 and shRNA xenograft tumours. DAPI, blue. (n=3, independent prostate samples, 5 fields acquired 
and scale bar represents 20 µm). (p) Western blot analysis of indicated proteins in 22Rv1 cells infected with 
shPDHA1 or scramble control and treated with exogenous fatty acids in fatty acid-free media; oleate (25μM), 
palmitate (25 μM) or a combination of these two over a 6-day period. Uncropped images are in Supplementary 
Figure 15.  (n=3, independent cell cultures). Error bars indicate s.e.m. **P < 0.01; ***P < 0.001. n.s, not 
significant. 
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Supplementary Fig. 8 
Both nuclear PDC and mitochondrial PDC are required for prostate cancer cell proliferation. 
(a-g) Representative images of confocal microscopy for PDHA1 and the N-terminus mature form of SREBF1 
(n=3, independent cell cultures, 5 fields acquired for each group and scale bar represents 10 μm) (a), western blot 
analysis of indicated proteins (n=3) (b), representative images of PDHA1 and lipid droplets in confocal 
microscopy. Uncropped images are in Supplementary Figure 15. (n=3, independent cell cultures, 5 fields acquired 
for each group and scale bar represents 50 μm) (c), evaluation of tumour formation in xenotransplantation 
experiments (n=6, independent tumour samples) (d), tumour mass in xenotransplantation experiments (n=6, 
independent tumour samples) (e), representative micrographs in histopathological analysis (haematoxylin/eosin 
staining and indicated proteins) in xenotransplantation experiments (n=6, independent tumour samples, 5 fields 
acquired for each group and scale bar represents 50 µm) (f) and quantification of the percentage of Ki-67 positive 
cells in xenotransplantation experiments (n=6, independent tumour samples) (g) of shPDHA1 or shRNA control 
22Rv1 cells infected  with NES-PDHA1, NLS-PDHA1 alone or in combination. (h) Western blot analysis of 
indicated proteins in the 22Rv1 cells infected with two shPDHA1 and a scramble shRNA control and treated with 
SB-204990, a selective ACLY inhibitors at the dose of 30 μM which effectively arrest cell growth as shown in 
panel (i) in this figure or vehicle for 9 days (n=3, independent cell cultures). Uncropped images are in 
Supplementary Figure 15. (i,j) the relative cell number quantification of the 22Rv1 cells (i) and PC3 cells (j) 
infected with two shPDHA1 and a scramble shRNA control and treated with SB-204990, a selective ACLY 
inhibitors at the dose of 30 μM for 9 days (n=3, independent cell cultures). Error bars indicate s.e.m. *P < 0.05; 
**P < 0.01. n.s, not significant. 
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Supplementary Fig. 9 
Mitochondrial PDC inhibition compromises prostate cancer cell proliferation by reducing citrate 
production. 
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(a) Relative cell number quantification by crystal violet staining of shPDHA1 or shRNA control 22Rv1 or PC3 
cells infected with NES-PDHA1 and NLS-PDHA1 alone or in combination and treated with citrate (100 μM) or 
vehicle (n=3, independent cell cultures). (b) Western blot analysis of indicated proteins in nuclear and 
cytoplasmic fractions in 22Rv1 cells infected with PDK1 or empty vector control. Uncropped images are in 
Supplementary Figure 15. (n=3, independent cell cultures) (c-e) Tumour mass in xenotransplantation experiments 
(n=6, independent tumour samples) (c), representative micrographs in histopathological analysis 
(haematoxylin/eosin staining and indicated proteins) (n=6, independent tumour samples and scale bar represents 
50 µm) (d) and relative cell number quantification by crystal violet (n=3, independent cell cultures) (e) of 
shPDHA1 or shRNA control 22Rv1 cells infected with PDK1 or empty vector control. Error bars indicate s.e.m. 
*P < 0.05; **P < 0.01; ***P < 0.001. n.s, not significant. 
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Supplementary Fig. 10 
Pharmacological inhibition of PDHA1 arrests mouse and human prostate tumours. 
(a,b) Representative structures, selected from MD simulations of the PDHA1/pyruvate (a) and PDHA1/3-FP (b) 
complexes. The a and b chains are represented as magenta and green ribbons, respectively. In the picture of 
PDHA1/3-FP complex, the fluorine atom is depicted in violet. Binding Delta G values, estimated by MM-GBSA, 
are also reported. (c) Upper panel, PDC activity measurements in the lysate from 22Rv1 cells treated with 3-FP 
or vehicle and supplemented with indicated amount of pyruvate in activity buffer of dipstick assay kit (n=3, 
independent cell cultures). Lower panel, quantification of PDC activity by mean optical density of colored bands 
shown on dipsticks in upper panel (n=3, independent cell cultures). (d) Body weight of mice of the indicated 
genotypes treated with 3-FP or vehicle from 8 weeks old for one month (n=3, independent mice). (e) Upper panel, 
PDC activity measurements, and quantification in anterior prostate of indicated genotypes from mice treated with 
3-FP or vehicle from 8 weeks old for one month (n=3, independent prostate samples). Lower panel, quantification 
of PDC activity by mean optical density of colored bands shown on dipsticks in upper panel (n=3, independent 
prostate samples). (f) Comparison of prostate lobe volumes from male mice at age of 12 weeks treated with 3-FP 
or vehicle for one month (mm3, 2 independent lobes per animal are presented. AP, anterior prostate; VP, ventral 
prostate; DLP, dorsal and lateral prostate, n=3, independent prostate samples). (g-j) Representative micrographs 
of histopathological analysis (haematoxylin/eosin and Ki-67 staining) of anterior prostates (AP) in Ptenpc-/-  
prostate tumours (n=3, independent prostate samples, 5 fields, and scale bar represents 50 µm) (g,h), 
quantification of the percentage of Ki-67 positive cells (n=3 independent prostate samples, 5 fields) (i) and 
quantification of the percentage of invasive prostate cancer glands in Ptenpc-/-  prostate tissue (n=3, independent 
prostate samples, 5 fields) (j) from male mice at age of 8 weeks treated with 3-FP or vehicle for one month. (k) 
Upper panel, PDC activity measurements and quantification in nuclear and cytoplasmic fractions of prostate 
tumours of indicated genotypes from mice at age of 8 weeks treated with 3-FP or vehicle for one month (n=3, 
independent prostate samples). Lower panel, fractionation was validated by western blot analysis for the indicated 
nuclear and cytosolic proteins. Uncropped images are in Supplementary Figure 15. (l) Western blot analysis of 
indicated proteins in prostate tumours from Ptenpc-/-  mice at age of 8 weeks treated with 3-FP or vehicle for one 
month (n=3, independent prostate samples). (m) Quantitative real time-PCR analysis of mRNA expression for 
Acly and Sqle from mice of indicated genotypes at age of 8 weeks treated with 3-FP or vehicle for one month 
(n=3, independent prostate samples). Error bars indicate s.e.m. *P < 0.05; **P < 0.01.  n.s, not significant. 
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Supplementary Fig. 11 
Pharmacological inhibition of PDHA1 arrests mouse and human prostate tumours. 
(a) Integrating enrichment analysis and pathway topology analysis of metabolic pathways in prostate tumours 
from Ptenpc-/-  mice at age of 8 weeks treated with or without 3-FP for one month (n=3, independent prostate 
samples). (b-e) Quantification of confocal microscopy for lipid droplets (Lipidtox; red) by lipid droplet counts 
per cell (b), average lipid droplets fluorescence (a.u) (c), lipid droplet counts per mm2 (d), average lipid droplets 
area in µm2 (e) in wild type and Ptenpc-/-  prostate tissues from 8 weeks old male mice treated with 3-FP or vehicle 
for one month (n=3, independent prostate samples, 5 fields). (f,g) Relative cell number quantification by crystal 
violet staining (f) and PDC activity measurements (g) in indicated prostate cancer cell lines treated with 3-
fluoropyruvic acid (3-FP) at the indicated concentration for 6 days (n=3, independent cell cultures). (h-j) 
Evaluation of tumour formation and quantification of the percentage of Ki-67 positive cells in xenotransplantation 
experiment in LNCaP (h), 22Rv1 (i) and PC3 (j) cells treated with 3-FP or vehicle for two months (n=6, 
independent tumour samples, 5 fields and scale bar represents 50 µm). (k) Schematic representation of the role 
of mitochondrial and nuclear PDH complex functions in regulating glucose influx of TCA cycle and controlling 
the diversion of TCA cycle intermediates (or glutamine derived anaplerosis pathway) into lipogenesis. (l) 
Metabolic landscape describing the functional relevance of PDC complex in regulating non-canonical tumour 
metabolism. Contrast to classic ‘Warburg effect' where cancers rely predominantly on glycolysis and catabolic 
TCA cycle gets restrained, tumours could achieve another ‘anabolism oriented' reprogramming/axis by 
upregulating PDC and promoting PDC nuclear translocation. Nuclear PDC controls the transitory process in TCA 
cycle by allowing the short-lived entry and exit of carbon pool in mitochondria to fuel citrate synthesis and 
lipogenesis. Taking advantage of this diversion caused by nuclear PDC, the tumour cells reduce carbon 
consumption in TCA cycle thereby benefiting proliferation. PDC inactivation arrests nuclear PDC active cancers 
by abrogating both glucose influx and potential anaplerosis pathways from reductive carboxylation and 
glutaminolysis.  The blue represents the pathways controlled by PDC. Error bars indicate s.e.m. **P < 0.01; 
***P < 0.001. n.s, not significant. 
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Supplementary Fig. 12 
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Uncropped full-length pictures of Western blotting membranes presented in the main Fig. 1a, 1g, 1k, 2b 
and 2c 
Membranes were often cut to enable blotting for multiple antibodies 
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Supplementary Fig. 13 
 56 
Uncropped full-length pictures of Western blotting membranes presented in the main Fig. 4a, 4b, 5f and 
Supplementary Fig. 1j 
Membranes were often cut to enable blotting for multiple antibodies 
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Supplementary Fig. 14 
Uncropped full-length pictures of Western blotting membranes presented in the Supplementary Fig. 3f, 
3m, 5a and 5c 
Membranes were often cut to enable blotting for multiple antibodies 
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Supplementary Fig. 15 
Uncropped full-length pictures of Western blotting membranes presented in the Supplementary Fig. 5l, 
7p, 8b, 8h, 9b and 10k 
Membranes were often cut to enable blotting for multiple antibodies 
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6. Materials and Methods 
Animals 
All mice were maintained under specific-pathogen-free conditions in the animal facilities of the 
IRB Institute, and experiments were performed according to state guidelines and approved by the 
local ethics committee. The PtenloxP and Pdha1loxP conditional knockout alleles have been 
described15,18.  Female PtenloxP/loxP; Pdha1loxP/Y mice were crossed with male Probasin-Cre4 (Pb-
Cre4) transgenic mice14 for the prostate-specific deletion of Pten and Pdha1. For genotyping, tail 
DNA was subjected to polymerase chain reaction analysis with the primers listed in Supplementary 
Table 1. Mice of correct genotypes were randomly chosen and allocated into experimental groups. 
For the transgenic mice, the experiment was carried on in single blind.  
Cell culture and reagents 
Human prostate carcinoma cell lines, 22Rv1, LNCaP, PC3, and DU145 were purchased from 
American Type Culture Collection (ATCC) and human prostate epithelial PNT2C2 cell line55 was 
gifted from Prof. Norman James Maitland, University of York and kept in Institute of Oncology 
Research (IOR) in Bellinzona, Switzerland. The cells were cultured in RPMI medium 1640 
(Catalog# 21875034, Thermo Fisher Scientific) with 10% fetal bovine serum (FBS) (Catalog# 
10500-064, Thermo Fisher Scientific), 10,000 I.U./mL Penicillin and 10,000 (μg/mL) 
Streptomycin (Catalog# P4333-20ML, Sigma) under the condition of 37 ℃ and 5% CO2. Cells 
were transduced with TRIPZ doxycycline inducible lentiviral construct against human PDHA1 
gene (Catalog# V2THS_75677, Dharmacon) and TRIPZ Inducible Lentiviral Empty Vector 
shRNA Control (Catalog# RHS4750, Dharmacon). Flat bottom ultra low attachment multiple well 
plates (Catalog# 3473, Corning) were used for sphere formation assay. Cells were transduced with 
pLKO lentiviral constructs against human PDHA1 gene (Catalog# SHCLNG-NM_000284, Sigma, 
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clone# shPDHA1-1: TRCN0000028582 and shPDHA1-2: TRCN0000028627) and Lentiviral 
Empty Vector shRNA Control (Catalog# SHC002, Sigma). PDHA1 was PCR-amplified from 
complementary DNA of a normal human prostate sample. For the overexpression of cytosol and 
nuclear-localized PDHA1, nuclear export signal (NES) or nuclear localization signal (NLS) was 
fused PDHA1 as NES-PDHA1 and NLS-PDHA1. NES-PDHA1 and NLS-PDHA1 constructs 
were engineered as sh-PDHA1 (Catalog# SHCLNG-NM_000284, Sigma, clone# shPDHA1-1: 
TRCN0000028582) resistant vectors. NES-PDHA1 and NLS-PDHA1 were cloned into pLenti 
CMV Neo (Addgene) and the empty vector was used as a control. Cells were infected shRNA 
control or shPDHA1 and overexpressed PDK1 by pLZRS-PDK1-IRES-puro or FG12-eGFP 
control19 (gifted from Prof. Daniel Peeper, The Netherlands Cancer Institute). Lentiviral and 
retroviral infections were performed using HEK293T cells and Phoenix cells, respectively, as 
producers of viral supernatants. Primary MEFs were derived from littermate embryos and obtained 
by crossing Pdha1loxP/loxP or PtenloxP/loxP animals. Embryos were harvested at 13.5 days post coitum, 
and individual MEFs were produced and cultured as previously described14-16. For senescence 
experiments, MEFs were infected with pMSCV hygro-Cre (Plasmid #34565, Addgene) or empty 
vector control (pMSCV hygro) retrovirus, selected pharmacologically in hygromycin (50 µg/mL, 
Catalog# H0654-250MG, Sigma) for 48 hr. After selection, cells were seeded and analyzed for 
SA-β-gal activity (Catalog #9860, Cell Signaling Technology). Cell number quantification with 
crystal violet was performed as referenced15. The chemicals used for cell and tumour treatments 
were purchased from Sigma: Doxycycline hyclate (Catalog# D9891-1G, Sigma) and β-
Fluoropyruvic acid sodium salt monohydrate (3-Fluoropyruvate, 3-FP, Catalog #F4004, Sigma). 
SB-204990 (Catalog# 4962, Bio-Techne AG). For the xenograft experiments, 2×106 22Rv1 cells 
infected Tripz-shPDHA1 or Tripz-shRNA control were injected subcutaneously (s.c.) into the 
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lower flank of the same nude mouse on different sides. The mice started to be fed with Doxycycline 
(0.2 g/L) water supplemented with 5% sucrose in another day. Tumour formation from each 
individual injection was monitored every three days until the 22nd day of experimental termination. 
2×106 22Rv1 cells infected shRNA control or shPDHA1 and overexpressed PDK1 by pLZRS-
PDK1-IRES-puro or FG12-eGFP control19 (gifted from Prof. Daniel Peeper, The Netherlands 
Cancer Institute) were injected subcutaneously (s.c.) into the lower flank of the same nude mouse 
on different sides. Tumour formation from each individual injection was monitored every three 
days until the 30th day of experimental termination. For experiments with xenograft, mice were 
excluded when the tumour size exceeded the average tumour size at the moment of randomization. 
The experiments with Xenograft (including tumour measurements) were carried on in single blind. 
For preclinical treatment on Ptenpc-/- males, 80 mg/Kg of 3-FP were intraperitoneally injected 
every three days on mice of ages at 8 weeks to 12 weeks. For the xenograft tumours treated with 
3-FP or vehicle control, 2×106 LNCaP, PC3, and 22Rv1 cells were injected subcutaneously (s.c.) 
into the lower flank of the nude mice. The treatment started when tumour size reached 100 mm3 
and the treatment continued for a period of two months. When the mice were sacrificed, tumours 
were disserted and analyzed. Mice were fasted for 6 h prior to tissue harvest (9 am-3 pm) in order 
to prevent metabolic alterations due to immediate food intake. 
Real-time PCR, western blotting, and immunohistochemistry  
RNA was extracted using TRIzol® Plus RNA Purification Kit (Catalog# 12183555, Life 
technologies). 1 μg of total RNA was used for cDNA synthesis using SuperScript® III Platinum® 
One-Step qRT-PCR Kit (Catalog# 11732-020, Life technologies). Quantitative Real Time PCR 
(q-RT PCR) was performed as previously described15. Primers employed are detailed in 
Supplementary Table 2. All qRT-PCR data presented was normalized using β-actin. Tissue and 
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cell lysates were prepared with RIPA buffer (1× PBS, 1% NP-40, 0.5% sodium deoxycholate, 
0.1% SDS and protease inhibitor cocktail (Catalog# 78429, Thermo Scientific)). The following 
antibodies were used for western blotting: rabbit polyclonal anti-Pten antibody (Catalog # 9552, 
Cell Signaling Technology), mouse monoclonal anti-PDHA1 antibody (Catalog # 459400, 
Invitrogen), rabbit polyclonal anti-phospho-PDHE1-A type I (Ser293) antibody (Catalog# 
ABS204, EMD Millipore), goat polyclonal anti-PDC-E2 Antibody (N-20) (Catalog# sc-16890, 
Santa Cruz Biotechnology), mouse monoclonal anti-DLD Antibody (E-3) (Catalog# sc-376890, 
Santa Cruz Biotechnology), rabbit polyclonal anti-PDP1 antibody (Catalog# HPA019081, Sigma), 
rabbit polyclonal anti-Akt antibody (Catalog# 9272, Cell Signaling Technology), rabbit 
monoclonal anti-p-Akt Ser473 antibody (Catalog# 4060, Cell Signaling Technology), rabbit 
monoclonal anti-Acetyl-Histone H3 (Lys9) antibody (Catalog# 9649, Cell Signaling Technology), 
rabbit monoclonal anti-Histone H3 antibody (Catalog# 4499, Cell Signaling Technology), rabbit 
polyclonal anti-ACLY antibody (Catalog# 4332, Cell Signaling Technology), goat polyclonal anti-
SQLE antibody (Catalog# sc-49754, Santa Cruz Technology), rabbit monoclonal anti-VDAC1 
(Catalog# 4661, Cell Signaling Technology), rabbit polyclonal anti-α-Tubulin antibody (Catalog# 
2144, Cell Signaling Technology) and mouse monoclonal anti-β-actin (Catalog# A5316, Sigma). 
For immune-histochemistry (IHC), tissues were fixed in 10% formalin and embedded in paraffin 
in accordance with standard procedures. Sections were stained with Rabbit polyclonal anti-PTEN 
antibody (Catalog# 51-2400, Thermo Fisher Scientific), mouse monoclonal anti-PDHA1 
(Catalog# 459400, Invitrogen), rabbit polyclonal Anti-PDP1 (Catalog# HPA019081, Sigma), anti-
Ki-67 (clone SP6, Lab Vision), or anti-cleaved-caspase-3 (Catalog#9661, Cell Signaling 
Technology) antibodies.  Prostate disease spectrum tissue array, including TNM, clinical stage and 
pathology grade, 80 cases/80 cores were purchased from US Biomax, Inc, (Catalog# PR8011a) 
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and prostate cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases/48 
cores was purchased from US Biomax, Inc (Catalog# PR483b). Ki-67 and gland invasiveness 
assessment was performed by three prostate pathologists independently, in a blinded manner. 
Gene Expression Analysis 
Gene expression profiling (GEP) was done using the MouseRef-8 v2.0 Expression BeadChip 
(Illumina, San Diego, CA, USA), following the manufacturer’s protocol. Arrays were read on an 
Illumina HiScanSQ system. Data were first extracted with the Illumina GenomeStudio software 
and then imported in Genomics Suite 6.4 (Partek Incorporated, Saint Louis, MO USA) and 
quantile normalized. Transcripts with differences in expression were identified by ANOVA. 
Enrichment analysis was performed using Gene Set Enrichment Analysis (GSEA) 56. Raw data 
have been deposited in National Center for Biotechnology Information’s Gene Expression 
Omnibus (GEO) and are accessible through GEO accession no. GSE74245. GSEA was 
performed on entire gene list ranked according to fold changes observed between Ptenpc-/- and 
Ptenpc-/-; Pdha1pc-/Y mice. The GS collection assessed includes all GSs smaller than 10 and larger 
than 500 (8335 out of 22423 GSs retained) compiled according to57 the 24.03.15. GSs yielding 
significance ((FDR <0.05; nominal p-value <0.005; TAGS ≥50%) were retained and assessed for 
their role in metabolic processes after visualizing the data as described 58. For the 3 relevant 
clusters identified, their GSs’ FDR q-values were, together with unaffected metabolic processes 
log2 transformed and inversed for display in Fig. 2a.  
Chromatin immunoprecipitation 
ChIP assays were performed with approximately 6 × 106 cells per experiment. Cells were subject 
to hypotonic lysis and treated with micrococcal nuclease to recover mono- to tri-nucleosomes. 
Nuclei were lysed by brief sonication and dialysed into N-ChIP buffer (10 mM Tris pH 7.6, 1 mM 
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EDTA, 0.1% SDS, 0.1% Na-Deoxycholate, 1% Triton X-100) for 2 h at 4 °C. Soluble material 
was incubated overnight at 4 °C after addition of 0.5–1 μg of antibody bound to 25 μl protein A 
Dynal magnetic beads (Catalog# 10006D, Invitrogen), with 5% kept as input DNA. Magnetic 
beads were washed, chromatin was eluted and ChIP DNA was dissolved in 10 mM Tris pH 8 for 
quantitative PCR reactions (see later). Three separate ChIP experiments were performed on 
replicate biological samples. The data shown are the average qRT–PCR values (n =3). Primers are 
listed below. All qPCR was performed using an Applied Biosystems StepOnePlus system and 
Power SYBR Green PCR master mix. ChIP samples were diluted 1:100 in H2O and 5 μl was used 
per reaction. ChIP-qPCR signals were calculated as per cent input. Primers used in ChIP were 
listed in supplementary table 3.  
Subcellular fractionation 
Nuclear and cytoplasmic fractionation was performed by centrifugation technique as described 
previously59. Nuclear and cytoplasmic extracts were made using NE-PER Nuclear and 
Cytoplasmic Extraction Reagent Kit (Catalog# 78833, Pierce Biotechnology). Total cell lysate 
was prepared in radioimmunoprecipitation assay buffer (RIPA; 25 mmol/L Tris (pH 7.4), 150 
mmol/L KCl, 5 mmol/L EDTA, 1% NP40, 0.5% sodium deoxycholate, and 0.1% SDS) with 
protease inhibitor cocktail (Catalog# 88688, Thermo Scientific). Proteins at the same amount were 
separated by 10% to 15% SDS-PAGE and transferred onto polyvinylidene difluoride membranes. 
For each fraction, nuclear protein histone 3 (Catalog# 4499, Cell Signaling Technology) and 
cytoplasmic protein α-Tubulin (Catalog# 2144, Cell Signaling Technology) were used to show 
clear isolation between nucleus and cytoplasm during fractionation. 
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Targeted mass spectrometry analysis 
For mouse prostate tissues, 500 µL of 80% LC-MS grade methanol was added to each 
approximately 15 mg sample and incubated at -80°C for 15 min. Tissue samples collected were 
centrifuged at 18, 470g for 5 min in a cold room to pellet cell debris and proteins. Supernatants 
were saved. Pellets were resuspended in 500 µl 80% methanol by vortexing and subsequently 
centrifuged as before. Supernatants were centrifuged one final time at 18, 470g for 10 min at 4°C. 
Metabolite extractions were dried to a pellet by SpeedVac with no heat. Samples were re-
suspended using 20 µL LC-MS grade water and 10 µL was injected and analyzed using a 5500 
QTRAP hybrid triple quadrupole mass spectrometer (AB/SCIEX) coupled to a Prominence UFLC 
HPLC system (Shimadzu) through selected reaction monitoring (SRM). Two hundred and sixty-
one endogenous water-soluble metabolites were targeted for steady-state analyses of samples. 
Some metabolites were targeted in both the positive and negative ion mode through a 
positive/negative polarity switching for a total of 296 SRM transitions. The ESI voltage was 
+4900V in the positive ion mode and -4500V in the negative ion mode. The dwell time was 3ms 
per SRM transition and the total cycle time was ~1.56 sec. Approximately 10-12 data points were 
acquired per detected metabolite. Samples were delivered to the MS through normal-phase 
chromatography using a 4.6mm i.d ×10 cm Amide XBridge HILIC column (Waters Corp.) at 350 
µl min-1. Gradients were run starting from 85% buffer B (HPLC grade acetonitrile) to 35% B from 
0-3.5 min; 35% B to 2% B from 3.5-11.5 min; 2% B was held from 11.5-16.5 min; 2% B to 85% 
B from 16.5-17.5 min; 85% B was held for 7 min to re-equilibrate the column. Buffer A was 
comprised of 20mM ammonium hydroxide/20mM ammonium acetate (pH 9.0) in 95:5 
water/acetonitrile. Peak areas from the total ion current for each metabolite SRM transition were 
integrated using MultiQuant v2.1 software (AB/SCIEX). Metabolomics data analysis was done in 
part using Metaboanalyst 2.0 software (www.metaboanalyst.ca). 
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Isotope Labeling and stationary Profiling 
Fresh transgenic mouse tumour tissues were mechanically dissociated, enzymatically digested and 
filtered to obtain a single-cell suspension as described60. Single cells were stained with fluorescein 
isothiocyanate (FITC)-anti-CD34 (Catalog# 560238, BD Biosciences) for stroma cells, FITC-anti-
Ter119 (Catalog# 557915, BD Biosciences) for erythrocytes, FITC-anti-CD31(Catalog# 561813, 
BD Biosciences) for endothelial cells, and FITC-anti-CD45 (Catalog# 553079, BD Bioscience) 
for leukocytes and incubated 20 min on ice. All antibodies (BD Biosciences) were used at 1:300; 
cells were then loaded into MS column with Anti-FITC MicroBeads (Catalog# 130-048-701, 
Miltenyi Biotec) for MACS separation, and unstained epithelial cells were collected in the negative 
fraction. For steady state metabolomic analysis5, prostate epithelial cells derived from transgenic 
mouse tumours were plated to ~80% confluence on 10 cm dishes in biological quadruplicate. cells 
were plated in RPMI medium (Catalog# 11875093, Thermo Scientific) was supplemented with 
10% dialyzed serum and devoid of glucose or glutamine and supplemented with one of the two 
carbon-13-labelled substrates [U-13C6]-glucose and [U-13C5] glutamine (Catalog# CLM-1396-1 
and CLM-1822-H-0.25, Cambridge Isotope Labs) where the remaining substrates were unlabelled 
(glucose 11 mM and glutamine 2 mM). Fatty acid oxidation studies20 were conducted using [U-
13C16] palmitate (Catalog# CLM-6059-1, Cambridge Isotope Labs) noncovalently bound to fatty 
acid-free BSA. [U-13C16] palmitate-BSA was added to culture medium at 5% of the final volume 
(50 mM final concentration) with 1 mM carnitine in medium formulated with delipidated FBS 
(Catalog# 12676011, Thermo scientific). Additionally, fresh media containing carbon-13-labelled 
substrates was exchanged 2 h prior to metabolite extraction for steady state analyses. Considering 
primary epithelial cells isolated from mouse prostate tissue do not attach and fit for long term 
culture, we labeled these epithelial cells for 6 h and we did not see the difference compared to the 
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results from labeling for 24 h. After 6 h of incubation with labelled substrates, metabolite 
extraction of medium was performed by adding 1mL cold (–80 °C) 80% methanol 
(Catalog#34966-1L and 14263-1L, Sigma), incubated at −80 °C for 30 min followed by 
centrifugation at 10,000g for 10 min at 4 °C. The resultant supernatant was lyophilized by speedvac 
and stored at − 80 °C until analysis. Dried metabolite pellets were re-suspended in 20 μL LC–MS 
grade water, 5 μL was injected onto a Prominence UFLC and separated using a 4.6 mm i.d. Å~ 
100 mm Amide XBridge HILIC column at 360 μL per minute starting from 85% buffer B (100% 
ACN) to 0% B over 16 min. Buffer A: 20 mM NH4OH/ 20 mM CH3COONH4 (pH = 9.0) in 95:5 
water/ACN.287 selected reaction monitoring (SRM) transitions were captured using positive/ 
negative polarity switching by targeted LC-MS/MS using a 5500 QTRAP hybrid triple quadrupole 
mass spectrometer. As for metabolomics, the quantity of the metabolite fraction analyzed was 
adjusted to the corresponding protein concentration from a sample processed in parallel. The 
analysis was performed for each of the three substrates on three independent tumours in biological 
triplicate.  
Lipidomics analysis on transgenic mouse prostate tumours 
~ 5 mg of solid tissue was snap frozen in liquid nitrogen (−196°C) as close to the time of resection 
as possible. Chloroform: methanol (2:1 ratio) was added to a final volume 20 times the volume of 
the biological sample (100 µL in 2 mL of solvent mixture) in a 12 mL glass vial. The mixture was 
agitated for 30 min in an orbital shaker at room temperature. 0.2 volume parts of water (400 µL 
for 2 mL) was added and the mixture was vortexed for 1 min. The mixture was placed still for 10 
min and centrifuge at low speed (1000 g) to separate into three phases. The upper aqueous phase 
was kept (optional) to analyze small organic polar molecules. The middle layer contains protein, 
DNA, and polar large molecules. The lower phase containing non-polar lipids was collected and 
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evaporated under vacuum using a SpeedVac rotary evaporator or under a nitrogen stream. 10 µL 
of sample was injected onto LC-MS/MS using a hybrid QExactive Plus Orbitrap mass 
spectrometer in DDA mode using positive/negative ion polarity switching (Top 8 in both modes). 
Using a 100 mm x 2.0 mm C18 column at 260 µL/min with a 1100 quaternary HPLC, lipids were 
eluted over 20 min. from 32% B buffer (90% IPA/10% ACN/10 mM NH4HCO2/0.1% FA) to 97% 
B. A buffer consisted of 59.9% ACN/40% water/10 mM NH4HCO2/0.1% FA. Lipid molecules 
were identified and quantified using LipidSearch 4.1.9 software61.  
Statistics 
For each independent in vitro experiment, at least three technical replicates were used 
(exceptions: in western blot analysis technical replicates are presented, in targeted metabolomics 
three technical replicates were used. For data mining analysis, Analysis of variance (ANOVA) 
test was used for multi-component comparisons and Student T test for paired-comparisons. In 
the in vitro experiments, data groups were assessed for normal distribution and Student T test 
was applied for paired-comparison. Data represent mean ± s.e.m. of pooled experiments unless 
otherwise stated. n values represent the number of experimental samples and all the experiments 
were repeated at least three times. For in vivo experiments, the equal variance could not be 
assumed and a non-parametric Mann-Whitney test was used. The confidence level used for all 
the statistical analyses was of 0.95 (alpha value = 0.05). Two-tail statistical analysis was applied 
for experimental design without predicted result, and one-tail for validation experiments 
(*P < 0.05; **P < 0.01; ***P < 0.001). 
Data availability 
The mouse gene expression datasets are available at 
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE74245 
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For cellular, molecular and metabolic assays, the lipidomics analysis on prostate cancer cell line, 
fatty acid rescue assay and computer simulations of 3-FP and PDC docking, the methods are 
available in Supplementary Note. 
URLs 
Gene Expression Omnibus, https://www.ncbi.nlm.nih.gov/geo/; MetaboAnalyst, 
http://www.metaboanalyst.ca/; UCSC Genome Browser on Human, https://genome.ucsc.edu/cgi-
bin/hgTracks?db=hg38&lastVirtModeType=default&lastVirtModeExtraState=&virtModeType=
default&virtMode=0&nonVirtPosition=&position=chr8%3A124998506-
125022283&hgsid=641911343_mdAzqHRm9nypyskAklqb2aiYGn1X 
 
Supplementary Methods 
Cellular, molecular and metabolic assays 
Lactate production was performed according to technical specifications using Lactate colorimetric/ 
Fluorometric assay kit (Catalog# K607-100, Biovision Incorporated). Acetyl-CoA production was 
measured using PicoProbe™ Acetyl-CoA Fluorometric Assay Kit (Catalog# K317-100, Biovision 
Incorporated). NADH/NAD+ ratio measurement was performed using NAD/NADH Quantitation 
Colorimetric Kit (Catalog# K337-100, Biovision Incorporated). ATP/ADP ratio measurement was 
performed using ADP/ATP Ratio Bioluminescence Assay Kit (Catalog# K255-200, Biovision 
Incorporated). PDH activity in cell or tumour lysates were measured using the DipStick assay 
kit19,23,48 (Catalog# MSP90, MitoSciences). Cells were lysed in the sample buffer provided by the 
manufacturer, followed by centrifugation and measurement of the protein concentration with the 
BioRad Protein Assay. Eighty micrograms of lysates from the whole cell or nuclear fractionation 
were loaded and PDH activity was measured according to the manufacturer's protocol. Oxygen 
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consumption rate (OCR) was measured with a XFp extracellular flux analyzer (Seahorse 
Bioscience). Briefly, 45,000 cells per well were seeded in a XFp plate, and OCR measurements 
were normalized to protein amount analyzed by Pierce BCA Protein Assay Kit (Catalog# 23225). 
Cells were initially plated in 10% FBS DMEM media for 24 h, and 1h before measurements, media 
was changed to DMEM serum and bicarbonate free, with glutamine and glucose (10 mM). The 
mitochondrial stress test was carried out using the following concentrations of the injected 
compound: Oligomycin (1 μM). LipidTox (Catalog# H34477, Molecular Probes) and DAPI 
(Catalog# H-1200, Vector Laboratories) were used on prostate cryostat section slide at the 
concentrations suggested by manufacturer’s protocols and images were acquired with a TCS SP5 
confocal microscope (Leica). Images of prostate glands tissue sections stained with DAPI and 
LipiTox were acquired with a Leica TCS SP5 confocal microscope, using a 63X/1.4 N.A. objective 
(Leica HCX PL APO lambda blue 63.0×1.40 OIL UV); 5 different fields of view of 100 μm × 100 
μm were acquired for each genotype. Lipid droplets segmentation and fluorescence analysis were 
performed using a custom-developed pipeline in CellProfiler (Broad Institute) open-source 
software62. 
Lipidomics analysis on prostate cancer cell line 
~ 4 million adherent cells were harvested and suspended in 450 µL PBS. The cells were pottered 
for 20 sec, snap frozen in liquid nitrogen and defrozen with 37 °C water. The cell lysate was 
centrifuged for 15 min at 14000 rpm. 420 µL supernatant of cell lysate was collected and each 
pellet was suspended in 420 µL PBS. Gas chromatographic runs were performed with helium as 
carrier gas at 0.6 mL/min. The split inlet temperature was set to 250 °C and the injection volume 
of 1 μL. A split ratio of 1:50 was used. The GC oven temperature ramp was from 50 °C to 300 °C 
at 5 °C/min for the longer column and from 35 °C to 300 °C at 25 °C/min for the shorter column. 
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The data acquisition rate was 10 Hz in both cases. For the TOF-MS, an EI source (70 eV) was 
used, and full-scan spectra (mass range from 50 to 550 amu) were recorded in the positive ion 
mode. The ion source and transfer line temperatures were set, respectively, to 200 °C and 250 °C. 
The web-based metabolomic data processing tool MetaboAnalyst 3.0 63was used to obtain a global 
metabolic profiling of cholesterol and its esterified derivatives among prostate cancer cells infected 
with two shPDHA1 and a scramble control on mass spectra data. The Partial Least Squares-
Discriminant Analysis (PLS-DA), a supervised multivariate statistical analysis method, was used. 
Variable Importance in Projection (VIP), which is a weighted sum of squares of the PLS loadings, 
was thereafter calculated and utilized to discriminate among groups.   
Radiolabelled Glucose and Glutamine Uptake, Fatty Acid and Cholesterol synthesis 
Cells were doxycycline treated for 5 days and then seeded in triplicate 24 hrs prior to the 
experiment in complete media. For uptake assay, the radioactive substrates were added to the cells 
in a buffered solution (140 mM NaCl, 20 mM Hepes/Na, 2.5 mM MgSO4, 1 mMCaCl2, and 5 mM 
KCl, pH 7.4) and incubate for 15 minutes at 37°C. Cells were subsequently washed with cold PBS 
and lysed with 0.1 M NaOH.  The lysates were resuspended and transferred to scintillation vials 
for counting. For fatty acid synthesis analysis, media were changed to RPMI + 10% or 1% serum 
supplemented with 2 µCi 14C-glucose or 14C-glutamine at 16 h prior to the end of the experiment. 
The cells were washed three times in ice cold PBS and then lysed in radioimmunoprecipitation 
assay (RIPA) buffer. Samples were first resuspended in 4 volumes of a CHCl3: MeOH (1:1) 
solution and then an additional volume of dH2O was added. The solution was then centrifuged at 
1000 rpm for 5 minutes at room temperature. The lower phase was collected and an equivalent 
volume of each sample was dried under a nitrogen stream before resuspension in ethanol, transfer 
to a scintillation vial and counted on the scintillation counter. Data were normalized to protein 
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levels. For cholesterol synthesis analysis, media were changed to RPMI + 10% or 1% serum 
supplemented with 2 µCi 14C-glucose or 14C-glutamine at 16 h prior to the end of the experiment. 
Cells were lysed directly in methanol and subject to lipids separation as described above. The 
lower phase was evaporated and then dissolved in CHCl3:CH3OH (2:1, vol:vol). Lipids were 
separated by thin layer chromatography on Aluminum TLC Silica plate (Merck, Germany). Plates 
were developed sequentially with solvent A (toluene:diethyl ether:ethyl acetate:acetic 
acid,75:10:13:1.2, by vol) to 8 cm above the level of application and dried under nitrogen. The 
TLC plates were then developed with solvent B (hexane:diethyl ether:formic acid, 80:20:2, v/v/v) 
to 14 cm above the level of application64. After air-drying of the plates, the samples were made 
visible by iodine vapor staining. Cholesterol (Sigma) was dissolved in CHCl3:CH3OH (2:1, vol:vol) 
and 20 μg were developed in parallel to the samples to determine the exact migration front and the 
bands to cut for the quantification. The aluminum plates were cut in correspondence to the 
cholesterol band and the radioactivity was counted using a Beckman LS1000 β-Counter. 
Fatty acid rescue assay 
For fatty-acid rescue, palmitate and oleate were dissolved in ethanol and complexed to 5% (w/v) 
fatty acid-free bovine serum albumin (Catalog# A8806-1G, Sigma) in PBS. The fatty acid mixture 
was directly added to RPMI media (Catalog# 21875034, Thermo Fisher Scientific) containing 
delipidated serum (Catalog# 12676011, Thermo scientific) to make the fatty-acid free medium. 
Cells were supplemented with either fatty acids conjugated to BSA or BSA alone for 6 days30. 
Computer simulations 
The X-ray structure of human PDHA1 (PDB code 1NI4 65) was used as starting model for 
molecular dynamics (MD) simulations. The exact positions of the pyruvate and of the catalytically 
relevant waters, not present in the 1NI4 crystal structure, were obtained by structural superposition 
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with the PDH structure from Geobacillus stearothermophilus (pdb code 3DV0 66). Furthermore, 
the structure of the 3-FP/PDHA1 complex was obtained by replacing a hydrogen in the pyruvate 
methyl group with a fluorine atom. The two molecular complexes were fully solvated in a TIP3P 
water box67  with a minimum distance of 10 Å from the protein surface and the charge neutrality 
of the systems was restored by adding a proper number of counter-ions. The protein and the water 
molecules were parameterized using the ff14SB force field68, while pyruvate, 3-FP, and Thiamine 
pyrophosphate (TPP) using the general amber force field (GAFF) parameters and atomic charges 
computed with the Am1-bcc scheme implemented in the AMBERTOOLS1569. Finally, 
monovalent ions were modeled with parameters proposed by Cheatham and coworkers70 and  Mg2+ 
with the parameterization of Li et al71. Energy minimizations and MD simulations were carried 
out with a van der Waals and short-range electrostatic cut-off of 8 Å, whereas the long-range 
electrostatic forces were taken into account with the Particle Mesh Ewald method72.  
The initial structures of the two complexes were energy minimized for 1000 steps to remove 
possible steric clashes. Then, the temperature was slowly increased to 300K in 30 ps.  
Subsequently, an MD simulation of 20 ns in the NPT ensemble (1atm, 300 K) was carried out with 
the pmemd.cuda code available in AMBER1473, to sample structures for the calculation of the 
binding free energy.  125 snapshots were extracted from the last 10ns of the MD simulations and 
the binding free energy for both pyruvate and 3-FP was estimated with the MM-GBSA method74. 
In particular, GB calculations were performed using the Hawkins, Cramer, Truhlar model75 and 
the Surface area (SA) was computed by the Connolly algorithm as implemented in MOLSURF76.  
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Supplementary Table 1 Primers for mouse or mouse prostate genotyping 
 
Supplementary Table 2 Primers for real-time PCR 
Gene (accession number) Forward primer sequence Reverse primer sequence Product length (bp) 
 Pdha1 (NM_008810) 5′-GAAATGTGACCTTCATCGGCT-3′ 5′-TGATCCGCCTTTAGCTCCATC-3′ 123 
Dlat (NM_145614) 5′-CTTTAGCCTCCAAAGCGAGAG-3′ 5′-AGATTGTAAATGTTCCACCCTGG-3′ 69 
Dld (NM_007861) 5′-GAGCTGGAGTCGTGTGTACC-3′ 5′-CCTATCACTGTCACGTCAGCC-3′ 138 
Pdp1 (NM_001098231)  5′-GCACCCATAGAGGACCGGA-3′  5′-CCTGCATGACCATCAAAAACCC-3′  83 
Pdp2 (NM_001024606)  5′-CTGTGTCCTACTGGATCTTCAA-3′  5′-CAGGTTCCTACTCGTGGCA-3′  99 
Pdk1 (NM_172665)  5′-GGACTTCGGGTCAGTGAATGC-3′  5′-TCCTGAGAAGATTGTCGGGGA-3′  122 
Pdk2 (NM_133667)  5′-AGGGGCACCCAAGTACATC-3′  5′-TGCCGGAGGAAAGTGAATGAC-3′  123 
Pdk3 (NM_145630)  5′-TCCTGGACTTCGGAAGGGATA-3′  5′-GAAGGGCGGTTCAACAAGTTA-3′  133 
PDK4 (NM_013743) 5′-AGGGAGGTCGAGCTGTTCTC-3′  5′-GGAGTGTTCACTAAGCGGTCA-3′  185 
Srebf1 (NM_011480) 5′- TGACCCGGCTATTCCGTGA -3′  5′-CTGGGCTGAGCAATACAGTTC-3′  61 
Srebf2 (NM_033218) 5′-GCAGCAACGGGACCATTCT-3′  5′-CCCCATGACTAAGTCCTTCAACT-3′ 200 
Sqle (NM_009270) 5′-ATAAGAAATGCGGGGATGTCAC-3′  5′- ATATCCGAGAAGGCAGCGAAC -3′  163 
Acly (NM_134037) 5′-ACCCTTTCACTGGGGATCACA-3′  5′-GACAGGGATCAGGATTTCCTTG-3′  65 
Acaca (NM_133360) 5′-GATGAACCATCTCCGTTGGC-3′ 5′-GACCCAATTATGAATCGGGAGTG-3′ 65 
Acacb (NM_133904) 5′-CCTTTGGCAACAAGCAAGGTA-3′ 5′-AGTCGTACACATAGGTGGTCC-3′ 123 
Fasn (NM_007988) 5′-GGAGGTGGTGATAGCCGGTAT-3′ 5′-TGGGTAATCCATAGAGCCCAG-3′ 140 
Scd1 (NM_009127.4) 5′-TTCTTGCGATACACTCTGGTGC-3′ 5′-CGGGATTGAATGTTCTTGTCGT-3′ 98 
Acss1 (NM_080575) 5′-GTTTGGGACACTCCTTACCATAC-3′ 5′-AGGCAGTTGACAGACACATTC-3′  101 
Acss2 (NM_019811) 5′-AAACACGCTCAGTAGCACCAC-3′  5′-AGCCAAGTAGGAAGCTCTCTC-3′  109 
Cpt1a (NM_013495) 5′-CTCCGCCTGAGCCATGAAG-3′  5′-CACCAGTGATGATGCCATTCT-3′  100 
Cpt2 (NM_009949) 5′-CAGCACAGCATCGTACCCA-3′  5′-TCCCAATGCCGTTCTCAAAAT-3′ 172 
 Cd36 (NM_001159556) 5′-ATGGGCTGTGATCGGAACTG-3′  5′-GTCTTCCCAATAAGCATGTCTCC-3′ 110 
Idh1 (NM_010497) 5′-ATGCAAGGAGATGAAATGACACG-3′  5′-GCATCACGATTCTCTATGCCTAA-3′  116 
Idh2 (NM_173011) 5′-GGAGAAGCCGGTAGTGGAGAT-3′  5′-GGTCTGGTCACGGTTTGGAA-3′  139 
Idh3a (NM_029573) 5′-TGGGTGTCCAAGGTCTCTC-3′  5′-CTCCCACTGAATAGGTGCTTTG-3′  177 
Idh3b (NM_130884) 5′-TGGAGAGGTCTCGGAACATCT-3′  5′-AGCCTTGAACACTTCCTTGAC-3′  150 
Genomic mutation Forward primer sequence Reverse primer sequence Product length (bp) 
PtenloxP/loxP 5′-AAAGTTCCCCTGCTGATGATTTGT-3′ 5′-TGTTTTTGACCAATTAAAGTAGGCTGTG-3′ loxP allele=480, Wild type allele=350 
Ptenpc-/- 5′-AAAGTTCCCCTGCTGATGATTTGT-3′ 5′-TTCTCTTGAGCACTGTTTCACAGGC-3′ Mutant allele=~1000, Wild type allele=N/A 
Pdha1loxP/loxP 5′-CGTTGTTGAGAGAGCAGCA-3′ 5′-CGCACAAGATATCCATTCCA-3′ loxP allele=380, Wild type allele=303 
Pdha1pc-/Y 5′-CGTTGTTGAGAGAGCAGCA-3′ 5′-CGCACAAGATATCCATTCCA-3′ Mutant allele=~300, Wild type allele =~800 
Probasin-Cre4 5′-CTTCTGTGGTGTGACATAATTGG-3′ 5′-GATGAGTTTGGACAAACCACAAC-3′ Tg(Pbsn-cre)4Prb=393 
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Idh3g (NM_008323) 5′-GGTGCTGCAAAGGCAATGC-3′  5′-TATGCCGCCCACCATACTTAG-3′  136 
Actb (NM_007393)  5′-GGCTGTATTCCCCTCCATCG-3′  5′-CCAGTTGGTAACAATGCCATGT-3′  154 
SREBF1 (NM_001005291) 5′-CGGAACCATCTTGGCAACAGT-3′  5′-CGCTTCTCAATGGCGTTGT-3′  141 
SREBF2 (NM_004599) 5′-AACGGTCATTCACCCAGGTC-3′  5′-GGCTGAAGAATAGGAGTTGCC-3′  133 
SQLE (NM_003129) 5′-GATGATGCAGCTATTTTCGAGGC-3′  5′-CCTGAGCAAGGATATTCACGACA-3′  88 
ACLY (NM_198830) 5′-TCGGCCAAGGCAATTTCAGAG-3′  5′-CGAGCATACTTGAACCGATTCT-3′  95 
ACACA (NM_198838) 5′-ATGTCTGGCTTGCACCTAGTA-3′ 5′-CCCCAAAGCGAGTAACAAATTCT-3′ 106 
ACACB (NM_001093) 5′-AGAAGACAAGAAGCAGGCAAAC-3′ 5′-GTAGACTCACGAGATGAGCCA-3′ 117 
FASN (NM_004104) 5′-AAGGACCTGTCTAGGTTTGATGC-3′ 5′-TGGCTTCATAGGTGACTTCCA-3′ 106 
SCD (NM_005063) 5′-TTCCTACCTGCAAGTTCTACACC-3′ 5′-CCGAGCTTTGTAAGAGCGGT-3′ 116 
ACSS1 (NM_001252676) 5′-CGTCCTTTTTGAGAGCACCC-3′ 5′-GCATCACCGTATTTCAGCAACA-3′ 129 
ACSS2 (NM_001242393) 5′-TTGGGGCTTTGCACTCCATT-3′ 5′-AGGCATCTGTAGTGATGAGAAGA-3′ 102 
CPT1A (NM_001876) 5′-ATCAATCGGACTCTGGAAACGG-3′ 5′-TCAGGGAGTAGCGCATGGT-3′ 121 
CPT2 (NM_000098) 5′-CTGGAGCCAGAAGTGTTCCAC-3′ 5′-AGGCACAAAGCGTATGAGTCT-3′ 78 
CD36 (NM_000072) 5′-CTTTGGCTTAATGAGACTGGGAC-3′ 5′-GCAACAAACATCACCACACCA-3′ 134 
IDH1 (NM_005896) 5′-CACCAAATGGCACCATACGAA-3′ 5′-CCCCATAAGCATGACGACCTAT-3′ 129 
IDH2 (NM_002168) 5′-CCCGTATTATCTGGCAGTTCATC-3′ 5′-ATCAGTCTGGTCACGGTTTGG-3′ 104 
IDH3A (NM_005530) 5′-CCCGCGTGGATCTCTAAGG-3′ 5′-AATTTCTGGGCCAATACCATCTC-3′ 129 
IDH3B (NM_006899) 5′-TAGTGCAGAATACGCAGTCTTTG-3′ 5′-CAGCATGTTGGAAGCCGAC-3′ 112 
IDH3G (NM_174869) 5′-GACCCGGCACAAGGACATAG-3′ 5′-GCTTGAAGGCATACTCGGCAA-3′ 155 
ACTB (NM_001101)  5′-CATGTACGTTGCTATCCAGGC-3′ 5′-CTCCTTAATGTCACGCACGAT-3′ 250 
 
 
Supplementary Table 3 Primers for Chromatin immunoprecipitation analysis 
 
Gene (Gene ID) Forward primer sequence Reverse primer sequence 
SQLE (6713) 5′-CTGATTCCTCTTTCGGACTCCC-3′ 5′-ACCGCAGCAGCCCCAGCTCCTG-3′ 
ACLY (47) 5′-TTTCAAGGCTTATCCCTACTCC-3′ 5′-TGCGTCAATCCTTCACTGTCCT-3′ 
E2F1 (1869) 5′-GTGTGGCGAAGAGCAGCAGGTC-3′ 5′-CCGTGAGCGTCATGGCCTTGGC-3′ 
CCND1 (595) 5′-TGGCGTTCTTGGAAATGCGCCC-3′ 5′-GTGGAGGTGGCTCTGCAGTAGG-3′ 
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